Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
Mult Scler
    June 2026
  1. CHEN H, Cortese M, Flores-Torres MH, Chen X, et al
    Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.
    Mult Scler. 2026 Jun 10:13524585261454827. doi: 10.1177/13524585261454827.
    >> Share

  2. HAMEDANI M, Lombardi G, Boffa G, Pistarini C, et al
    Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.
    Mult Scler. 2026 Jun 9:13524585261450820. doi: 10.1177/13524585261450820.
    >> Share

  3. BENALLEGUE N, Rollot F, Iaffaldano P, Lucisano G, et al
    A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.
    Mult Scler. 2026 Jun 1:13524585261446829. doi: 10.1177/13524585261446829.
    >> Share

  4. CORREALE J, Marrodan M, Piedrabuena MA, Soman K, et al
    Microbiome-derived metabolites from vitamin B2 and B9 pathways modulate MAIT cells from multiple sclerosis patients.
    Mult Scler. 2026 Jun 1:13524585261447695. doi: 10.1177/13524585261447695.
    >> Share

  5. LAULE C, Cohen-Adad J, Witt AA, De Luca GC, et al
    Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities.
    Mult Scler. 2026 Jun 1:13524585261444600. doi: 10.1177/13524585261444600.
    >> Share

  6. POSER PL, Gisevius B, Tokic M, Fisse AL, et al
    Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.
    Mult Scler. 2026 Jun 1:13524585261446846. doi: 10.1177/13524585261446846.
    >> Share

  7. MCCURDY S, Sheng E, Jalaleddini K, Datta G, et al
    Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMS.
    Mult Scler. 2026;32:711-721.
    >> Share

  8. TALLANTYRE EC, Apap Mangion S, Teunissen CE
    A framework for blood biomarker discovery in MS.
    Mult Scler. 2026;32:661-669.
    >> Share

    May 2026
  9. SANDESJO F, McKay KA, Fink K, Piehl F, et al
    Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study.
    Mult Scler. 2026 May 31:13524585261448789. doi: 10.1177/13524585261448789.
    >> Share

  10. TALLANTYRE EC, Planchon SM, Howard H, Mays J, et al
    Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).
    Mult Scler. 2026 May 31:13524585261449988. doi: 10.1177/13524585261449988.
    >> Share

  11. SARASTE M, Nikkila T, Matilainen M, Hamalainen P, et al
    TSPO-PET-measurable neuroinflammation associates with information processing speed decline in multiple sclerosis.
    Mult Scler. 2026 May 31:13524585261446839. doi: 10.1177/13524585261446839.
    >> Share

  12. CHANG G, Nasr Z, Schoeps VA, Virupakshaiah A, et al
    Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis.
    Mult Scler. 2026 May 29:13524585261444244. doi: 10.1177/13524585261444244.
    >> Share

  13. RUIZ-ALGUERO M, Ahmed SM, Zhu F, Zhao Y, et al
    Prescription drug dispensations 15 years before multiple sclerosis onset: A matched cohort study, British Columbia, Canada.
    Mult Scler. 2026 May 27:13524585261450813. doi: 10.1177/13524585261450813.
    >> Share

  14. AMINI F, Everett K, Zhu F, Li P, et al
    Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.
    Mult Scler. 2026 May 22:13524585261445372. doi: 10.1177/13524585261445372.
    >> Share

  15. BARBUTI E, Piervincenzi C, Baione V, Ojha A, et al
    Clinical, structural, and functional MRI features predicting PIRMA at 5-year follow-up in multiple sclerosis.
    Mult Scler. 2026 May 22:13524585261445318. doi: 10.1177/13524585261445318.
    >> Share

  16. POISSON KE, Anjum R, Gyang T, Eisner M, et al
    Impact of adverse childhood experiences on long-term quality of life in adults with pediatric-onset multiple sclerosis.
    Mult Scler. 2026 May 20:13524585261444237. doi: 10.1177/13524585261444237.
    >> Share

  17. NAZZI C, Turrini S, Pezzetta R, Scarpazza C, et al
    Transcranial magnetic stimulation in multiple sclerosis: Targeting symptoms through neuroplasticity.
    Mult Scler. 2026 May 19:13524585261442777. doi: 10.1177/13524585261442777.
    >> Share

  18. PALLADINO R, Marrie RA, Affinito G, Majeed A, et al
    Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023.
    Mult Scler. 2026 May 12:13524585261444243. doi: 10.1177/13524585261444243.
    >> Share

  19. LEVRAUT M, Cohen M, Sterlin D, Ayrignac X, et al
    Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study.
    Mult Scler. 2026 May 6:13524585261442020. doi: 10.1177/13524585261442020.
    >> Share

  20. AMIN M, Nakamura K, Thoomukuntla B, Carlson AK, et al
    Paramagnetic rim lesions on 7T MRI after autologous hematopoietic cell transplantation.
    Mult Scler. 2026;32:647-651.
    >> Share

    April 2026
  21. GUARNASCHELLI MF, Marrodan M, Sosa BE, Perez Arana CI, et al
    Early use of high-efficacy disease-modifying therapies reduces the risk of progression independent of relapse and MRI activity in patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2026 Apr 29:13524585261442036. doi: 10.1177/13524585261442036.
    >> Share

  22. SALTER A, Novak A, Lancia S, Cutter GR, et al
    Use of semaglutide and tirzepatide among people with multiple sclerosis.
    Mult Scler. 2026 Apr 29:13524585261442033. doi: 10.1177/13524585261442033.
    >> Share

  23. GRECH L, Allan M, Skvarc D, Hamer R, et al
    Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration.
    Mult Scler. 2026 Apr 26:13524585261435415. doi: 10.1177/13524585261435415.
    >> Share

  24. LEMBO F, Fantozzi R, Collura A, Buttari F, et al
    Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.
    Mult Scler. 2026 Apr 26:13524585261441504. doi: 10.1177/13524585261441504.
    >> Share

  25. PENG X, Bjornevik K, Clish CB, Edan G, et al
    Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.
    Mult Scler. 2026 Apr 26:13524585261435409. doi: 10.1177/13524585261435409.
    >> Share

  26. HOLLEN C, Garcia C, Hemond CC, Spain RI, et al
    Filtered-phase imaging versus susceptibility-weighted imaging for paramagnetic rim lesion detection in multiple sclerosis: A head-to-head comparison.
    Mult Scler. 2026 Apr 26:13524585261439651. doi: 10.1177/13524585261439651.
    >> Share

  27. BENVENISTE PL, Letourneau-Guillon L, Araujo D, Chougar L, et al
    Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers.
    Mult Scler. 2026 Apr 24:13524585261427333. doi: 10.1177/13524585261427333.
    >> Share

  28. TOUBASI AA, Lakhani DA, Moore J, Schilling K, et al
    Spinal cord imaging in multiple sclerosis: A vital component we can no longer overlook.
    Mult Scler. 2026 Apr 21:13524585261438770. doi: 10.1177/13524585261438770.
    >> Share

  29. TOLJAN K, Renner B, Daboul L, Martin ML, et al
    Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.
    Mult Scler. 2026 Apr 20:13524585261434218. doi: 10.1177/13524585261434218.
    >> Share

  30. FILIPPATOU AG, Sanjayan M, Dewey BE, Johnson E, et al
    Accelerometry-derived activity fragmentation as a predictor of brain atrophy and disability progression in multiple sclerosis.
    Mult Scler. 2026 Apr 20:13524585261435926. doi: 10.1177/13524585261435926.
    >> Share

  31. OZEN MS, Aksu Yildirim S
    Effects of motor imagery and action observation combined with standard rehabilitation on walking distance in people with multiple sclerosis: A single-blind exploratory randomized controlled trial.
    Mult Scler. 2026 Apr 16:13524585261435401. doi: 10.1177/13524585261435401.
    >> Share

  32. LEE HL, Lyou HJ, Jeong H, Son JH, et al
    Obstetric and neonatal outcomes in women with multiple sclerosis: A nationwide matched cohort study in Korea.
    Mult Scler. 2026 Apr 14:13524585261434195. doi: 10.1177/13524585261434195.
    >> Share

  33. GHAJARZADEH M, Mowry EM, Fitzgerald KC, Nourbakhsh B, et al
    Cardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue.
    Mult Scler. 2026 Apr 5:13524585261438014. doi: 10.1177/13524585261438014.
    >> Share

  34. PIERRET C, Androdias G, Lebrun-Frenay C, Vukusic S, et al
    Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.
    Mult Scler. 2026 Apr 5:13524585261437966. doi: 10.1177/13524585261437966.
    >> Share

  35. ANDERSEN ML, Anru PL, Sorensen E, Jolving LR, et al
    Treatment-requiring postpartum depression in mothers with multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2026 Apr 3:13524585261429255. doi: 10.1177/13524585261429255.
    >> Share

  36. CAMPAGNA MP, Bove R
    Menopause is a progression event in multiple sclerosis: Yes.
    Mult Scler. 2026 Apr 1:13524585261429827. doi: 10.1177/13524585261429827.
    >> Share

  37. STRIJBIS E, Mostert J, D'Haeseleer M, Moral E, et al
    Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials.
    Mult Scler. 2026;32:429-439.
    >> Share

  38. GIOVANNONI G
    Immunological and other multiple sclerosis prodromes.
    Mult Scler. 2026;32:355-358.
    >> Share

    March 2026
  39. BACCHETTI A, McCormack B, Lin TY, Filippatou AG, et al
    Influence of OSCAR-IB criteria on test-retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis.
    Mult Scler. 2026 Mar 29:13524585261426768. doi: 10.1177/13524585261426768.
    >> Share

  40. LANGER-GOULD AM, Smith JB, Nielsen AS, Beaber BE, et al
    De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.
    Mult Scler. 2026 Mar 19:13524585261430130. doi: 10.1177/13524585261430130.
    >> Share

  41. GUERRERO-FERNANDEZ MM, Serrano-Alvarez C, Foronda-Bengoa J, Barrero-Hernandez FJ, et al
    Intrathecal synthesis of Epstein-Barr virus antibodies 15 years before onset of multiple sclerosis.
    Mult Scler. 2026 Mar 17:13524585261427398. doi: 10.1177/13524585261427398.
    >> Share

  42. INOJOSA H, Mathias R, Dillenseger A, Voigt I, et al
    AI-enabled Living Labs: Accelerating innovation in multiple sclerosis care and research.
    Mult Scler. 2026 Mar 13:13524585261424136. doi: 10.1177/13524585261424136.
    >> Share

  43. NOVA A, Di Caprio G, Gentilini D, Bernardinelli L, et al
    A bidirectional two-sample Mendelian randomization study of immune responses against Epstein-Barr virus nuclear antigen 1 and multiple sclerosis in individuals of European ancestry.
    Mult Scler. 2026 Mar 10:13524585261423063. doi: 10.1177/13524585261423063.
    >> Share

  44. EBRAHIMI A, Wiil UK, Olsson T, Lio P, et al
    A susceptibility network analysis of disease trajectories leading to multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2026 Mar 10:13524585261421480. doi: 10.1177/13524585261421480.
    >> Share

  45. SPAGNOLO F, Gordaliza PM, Bhardwaj A, Lu PJ, et al
    A multi-modal deep learning network for the classification of paramagnetic rim and remyelinated lesions in multiple sclerosis.
    Mult Scler. 2026 Mar 6:13524585261421491. doi: 10.1177/13524585261421491.
    >> Share

  46. CORONA A, Clarelli F, Paakkonen K, Harroud A, et al
    Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.
    Mult Scler. 2026 Mar 3:13524585261417130. doi: 10.1177/13524585261417130.
    >> Share

  47. ABAD-INCHAURRONDO I, Lu S, Lui E, Susin-Calle S, et al
    Performance of the 2024 McDonald diagnostic criteria for multiple sclerosis.
    Mult Scler. 2026 Mar 3:13524585261421816. doi: 10.1177/13524585261421816.
    >> Share

  48. SIVA A, Kantarci O
    Multiple sclerosis controversies: Do MRI-negative relapses really exist? - Commentary.
    Mult Scler. 2026 Mar 3:13524585261423082. doi: 10.1177/13524585261423082.
    >> Share

  49. RIBONI-VERRI G, Gautam R, Chen B, Cunniffe NG, et al
    Myelination of the retinal nerve fibre layer: A case report.
    Mult Scler. 2026;32:347-350.
    >> Share

    February 2026
  50. SHINODA K, Matsuyoshi A, Takeuchi H, Watanabe M, et al
    Diagnostic performance of central vein sign, paramagnetic rim lesion and cortical lesion in Asian patients with multiple sclerosis.
    Mult Scler. 2026 Feb 26:13524585261420650. doi: 10.1177/13524585261420650.
    >> Share

  51. WENGER AL, Pagani E, Meani A, Preziosa P, et al
    Clinical and MRI substrates of Symbol Digit Modalities Test impairment in multiple sclerosis patients with an adult- and late-onset.
    Mult Scler. 2026 Feb 23:13524585261417265. doi: 10.1177/13524585261417265.
    >> Share

  52. COHEN M, Mondot L, Ayrignac X, Vukusic S, et al
    Comparison of individuals with radiologically isolated syndrome, early multiple sclerosis patients, and healthy controls using a digital neurological examination.
    Mult Scler. 2026 Feb 22:13524585261418921. doi: 10.1177/13524585261418921.
    >> Share

  53. SIAVOSHI F, Noroozi R, Chang G, Schoeps VA, et al
    Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis.
    Mult Scler. 2026 Feb 20:13524585261417120. doi: 10.1177/13524585261417120.
    >> Share

  54. SHALASH A, Gams Massi D, Ben Sassi S, Tibar H, et al
    Availability and affordability of therapies and services of multiple sclerosis in Africa: A continent-wide survey.
    Mult Scler. 2026 Feb 12:13524585261417591. doi: 10.1177/13524585261417591.
    >> Share

  55. SANGHA KS, Jakubecz C, Maynard M, Hernandez RS, et al
    Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study.
    Mult Scler. 2026 Feb 9:13524585251412125. doi: 10.1177/13524585251412125.
    >> Share

  56. MILLER A, Cohen JA, Karni A, Popper L, et al
    GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.
    Mult Scler. 2026;32:202-213.
    >> Share

  57. PATEL MA, Punnen TG, Shan KS, McCreary MC, et al
    Clinical and radiological outcomes of directed treatment transitions from Gilenya((R)) to generic fingolimod.
    Mult Scler. 2026;32:192-201.
    >> Share

    January 2026
  58. DI ANTONIO F, Brichetto G, Tacchino A, Pedulla L, et al
    Patient-reported outcomes as predictors of disability evolution in Multiple Sclerosis: An interpretable machine learning approach.
    Mult Scler. 2026 Jan 30:13524585251411093. doi: 10.1177/13524585251411093.
    >> Share

  59. BOLLO L, Pareto D, Tagliani P, Sceppacuercia S, et al
    Optic nerve imaging with OCT predicts disease progression and monitors brain and spinal atrophy in primary progressive multiple sclerosis.
    Mult Scler. 2026 Jan 30:13524585251407976. doi: 10.1177/13524585251407976.
    >> Share

  60. MARGONI M, Meani A, Pagani E, Preziosa P, et al
    Correlates of long-term clinical outcomes in pediatric multiple sclerosis: A 12-year study.
    Mult Scler. 2026 Jan 26:13524585251408639. doi: 10.1177/13524585251408639.
    >> Share

  61. PRETZSCH R, El Mahdaoui S, Johnson P, Soares MD, et al
    Neurofilament light chain as a surrogate candidate for disease activity in multiple sclerosis (LUMINOUS)-A meta-regression of randomized controlled trials.
    Mult Scler. 2026 Jan 23:13524585251407973. doi: 10.1177/13524585251407973.
    >> Share

  62. KUMARI S, Stephens S, Yoo PY, Arbour-Nicitopoulos KP, et al
    Built-environment correlates of physical activity in youth with multiple sclerosis.
    Mult Scler. 2026 Jan 20:13524585251407505. doi: 10.1177/13524585251407505.
    >> Share

  63. VAN DER WALT A
    Multiple sclerosis controversies: Detecting progressing events in MS clinics in real-time is possible-commentary.
    Mult Scler. 2026 Jan 14:13524585251409579. doi: 10.1177/13524585251409579.
    >> Share

  64. NESBITT C, Van Der Walt A, Butzkueven H, Rath L, et al
    Violence and multiple sclerosis: Towards an evidence-informed call to action in neurology.
    Mult Scler. 2026 Jan 13:13524585251409580. doi: 10.1177/13524585251409580.
    >> Share

  65. GUHA NIYOGI P, Sanjayan M, Ghosal R, Goldsmith J, et al
    Quantifying observable movement reserve in multiple sclerosis via upper diurnal activity quantiles.
    Mult Scler. 2026 Jan 1:13524585251398689. doi: 10.1177/13524585251398689.
    >> Share

  66. BERNSTEIN HR, Grouza V, Gati JS, Morrow SA, et al
    Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disability.
    Mult Scler. 2026;32:80-92.
    >> Share

  67. CALABRESI PA, Giovannoni G, Hartung HP, Naismith RT, et al
    Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
    Mult Scler. 2026;32:107-120.
    >> Share

  68. BORRELLI S, Guisset F, Farneti M, Stolting A, et al
    Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study.
    Mult Scler. 2026;32:69-79.
    >> Share

  69. LIZAK N, Sharmin S, Horakova D, Havrdova EK, et al
    Managing reactivation of multiple sclerosis during treatment with natalizumab.
    Mult Scler. 2026;32:121-133.
    >> Share

  70. MOROZUMI T, Preziosa P, Meani A, Pagani E, et al
    Contribution of structural and functional MRI in predicting response to motor training in multiple sclerosis.
    Mult Scler. 2026;32:93-106.
    >> Share

  71. RANUCCI D, Falco F, Nicolella V, Marra LA, et al
    Dysarthria assessment in multiple sclerosis patients.
    Mult Scler. 2026;32:134-143.
    >> Share

    December 2025
  72. RATZAN AS, Simani L, Dworkin JD, Buyukturkoglu K, et al
    Characterizing the extended language network in individuals with multiple sclerosis.
    Mult Scler. 2025 Dec 31:13524585251398451. doi: 10.1177/13524585251398451.
    >> Share

  73. DE NAPOLI G, Gotti E, Baldovini C, Di Sciascio L, et al
    Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 Dec 31:13524585251407501. doi: 10.1177/13524585251407501.
    >> Share

  74. ITO M, Masuda H, Morooka M, Sugiyama A, et al
    Gerstmann-Straussler-Scheinker disease mimicking primary progressive multiple sclerosis: A case with positive oligoclonal bands.
    Mult Scler. 2025 Dec 29:13524585251401053. doi: 10.1177/13524585251401053.
    >> Share

  75. KIM SH, Kang YR, Chung J, Joo M, et al
    Optimizing kappa free light chain index thresholds for multiple sclerosis (MS) diagnosis in low-MS prevalence regions: Insights from an Asian cohort.
    Mult Scler. 2025 Dec 27:13524585251399102. doi: 10.1177/13524585251399102.
    >> Share

  76. BRIGGS F, Nyati A, Zweig S, Leung LJ, et al
    Allergic phenotypes and asthma in multiple sclerosis: Epidemiologic and genetic relationships.
    Mult Scler. 2025 Dec 27:13524585251398382. doi: 10.1177/13524585251398382.
    >> Share

  77. MARRIE RA, Dobson R, Baranzini SE, Salvetti M, et al
    Toward a global research agenda for preventing multiple sclerosis.
    Mult Scler. 2025 Dec 26:13524585251398381. doi: 10.1177/13524585251398381.
    >> Share

  78. RATTI S, Eke H, Cantarutti A, Bonn SE, et al
    Mediterranean diet and risk of multiple sclerosis: A prospective cohort study.
    Mult Scler. 2025 Dec 15:13524585251396408. doi: 10.1177/13524585251396408.
    >> Share

  79. GOMEZ-FIGUEROA E, Casallas-Vanegas A
    The revised 2024 McDonald diagnostic criteria can solve the misdiagnosis problem in multiple sclerosis: NO.
    Mult Scler. 2025 Dec 13:13524585251396290. doi: 10.1177/13524585251396290.
    >> Share

  80. RAMANATHAN S, Solomon AJ
    The revised 2024 McDonald criteria can solve the misdiagnosis problem in multiple sclerosis: YES.
    Mult Scler. 2025 Dec 13:13524585251396284. doi: 10.1177/13524585251396284.
    >> Share

  81. VAN DER WALT A
    'The revised 2024 McDonald criteria can solve the misdiagnosis problem in multiple sclerosis': Commentary.
    Mult Scler. 2025 Dec 13:13524585251396271. doi: 10.1177/13524585251396271.
    >> Share

  82. BSTEH G, Marti S, Hammer H, Krajnc N, et al
    Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?
    Mult Scler. 2025 Dec 6:13524585251396283. doi: 10.1177/13524585251396283.
    >> Share

  83. KIM TB, Lee JY, Brinker A, Lee PR, et al
    Anaphylaxis and glatiramer acetate.
    Mult Scler. 2025;31:1664-1671.
    >> Share

  84. HARROUD A, Antel JP
    Neuroimmune interactions: How past lessons can inform the present and future of MS care.
    Mult Scler. 2025;31:1611-1618.
    >> Share

    November 2025
  85. DAUBY S, Dive D, Hansen I, Lommers E, et al
    Cladribine monotherapy in a patient with coexisting Crohn's disease and multiple sclerosis.
    Mult Scler. 2025 Nov 30:13524585251390859. doi: 10.1177/13524585251390859.
    >> Share

  86. BARBUTI E, Pozzilli C, Borriello G, Petracca M, et al
    Addressing autoimmune comorbidities in multiple sclerosis: A case report of ulcerative colitis remission in a patient treated with cladribine tablets.
    Mult Scler. 2025 Nov 30:13524585251396258. doi: 10.1177/13524585251396258.
    >> Share

  87. LU J, Brownlee WJ
    Cladribine: A useful treatment option in multiple sclerosis patients with autoimmune comorbidities.
    Mult Scler. 2025 Nov 30:13524585251396293. doi: 10.1177/13524585251396293.
    >> Share

  88. SHI Z, Wang H, Yan Z, Tang Y, et al
    T1-based stratification of paramagnetic rim lesions in multiple sclerosis: Evidence of microstructural heterogeneity and clinical implications.
    Mult Scler. 2025 Nov 10:13524585251389809. doi: 10.1177/13524585251389809.
    >> Share

  89. YANG JH, Race J, Sumowski P, Jacques K, et al
    Epigenetic age and telomere length correlations in pediatric-onset multiple sclerosis.
    Mult Scler. 2025 Nov 6:13524585251386217. doi: 10.1177/13524585251386217.
    >> Share

  90. SELMAJ KW, Steinman L, Comi G, Bar-Or A, et al
    Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
    Mult Scler. 2025;31:1557-1571.
    >> Share

  91. SANDGREN S, Maceski AM, Benkert P, Einsiedler M, et al
    Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.
    Mult Scler. 2025;31:1531-1542.
    >> Share

  92. VAN SCHEPENDOM J, Cutter G
    Lost in dichotomization: Preserving statistical power and sensitivity in MS cognitive research.
    Mult Scler. 2025;31:1513-1517.
    >> Share

    October 2025
  93. ZIEMSSEN T, Freedman MS, Bar-Or A, Montalban X, et al
    Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.
    Mult Scler. 2025 Oct 29:13524585251389797. doi: 10.1177/13524585251389797.
    >> Share

  94. BANKS SA, Baker MR, Flanagan EP, Permezel FE, et al
    Tremor and disability outcomes following deep brain stimulation for multiple sclerosis-associated tremor.
    Mult Scler. 2025 Oct 27:13524585251387935. doi: 10.1177/13524585251387935.
    >> Share

  95. BRIGGS FB, Yang J, Toljan K, Conway DS, et al
    Longitudinal modeling of upper extremity function in multiple sclerosis: Associations for clinical and sociodemographic factors.
    Mult Scler. 2025 Oct 26:13524585251384060. doi: 10.1177/13524585251384060.
    >> Share

  96. CHERTCOFF AS, Ruiz-Alguero M, Yusuf F, Zhao Y, et al
    Psychiatric morbidity during the multiple sclerosis prodrome is associated with future disability.
    Mult Scler. 2025 Oct 26:13524585251382801. doi: 10.1177/13524585251382801.
    >> Share

  97. BALSHI A, Feldman TB, Dempsey JP, Baber U, et al
    A multicenter cohort of transgender and gender diverse people with multiple sclerosis.
    Mult Scler. 2025 Oct 8:13524585251383330. doi: 10.1177/13524585251383330.
    >> Share

  98. BARBUTI E, Prosperini L, Ruggieri S, Haggiag S, et al
    How premorbid structural reserve affects disability accrual in multiple sclerosis.
    Mult Scler. 2025 Oct 8:13524585251372440. doi: 10.1177/13524585251372440.
    >> Share

  99. BORDET C, Maachi O, Papeix AC, Laigo P, et al
    Human papillomavirus-related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase(R).
    Mult Scler. 2025 Oct 8:13524585251377411. doi: 10.1177/13524585251377411.
    >> Share

  100. AJDINAJ P, Mongay-Ochoa N, Alberich M, Tintore M, et al
    Long-term impact of spinal cord reserve on disability accumulation in multiple sclerosis.
    Mult Scler. 2025 Oct 7:13524585251378995. doi: 10.1177/13524585251378995.
    >> Share

  101. SUTHIPHOSUWAN S, Lim TR, Hu Z, Colak E, et al
    Choroid plexus enlargement correlates with demyelinating lesions and thalamic atrophy in radiologically isolated syndrome.
    Mult Scler. 2025;31:1314-1325.
    >> Share

  102. FREEDMAN DE, Campbell KA, Feinstein A
    Affective reserve in multiple sclerosis.
    Mult Scler. 2025;31:1397-1400.
    >> Share

  103. REINSBERG HK, Oertel FC, Casillas D, Kaufhold G, et al
    Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.
    Mult Scler. 2025;31:1493-1505.
    >> Share

  104. PAISEY C, Curtin K, Epps SJ, Rice CM, et al
    Acute retinal necrosis associated with dimethyl fumarate.
    Mult Scler. 2025;31:1506-1508.
    >> Share

    September 2025
  105. GRAY-RONCAL K, Appiah MJ, Zorn K, Smith KC, et al
    Increased contact with clinical trial participants may improve confirmed multiple sclerosis relapse detection.
    Mult Scler. 2025 Sep 25:13524585251373002. doi: 10.1177/13524585251373002.
    >> Share

  106. LEAVITT VM, Simani L, Koch M, Morrow SA, et al
    The language and memory test: A brief multidomain digital cognitive measure for multiple sclerosis.
    Mult Scler. 2025 Sep 25:13524585251366096. doi: 10.1177/13524585251366096.
    >> Share

  107. RIVIER CA, Xu L, Clocchiatti-Tuozzo S, Zhao H, et al
    Differential results of genetic risk scoring for multiple sclerosis in European and African American populations.
    Mult Scler. 2025 Sep 24:13524585251377607. doi: 10.1177/13524585251377607.
    >> Share

  108. UYSAL TAN F, Tan MO
    Comment on 'short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis'.
    Mult Scler. 2025 Sep 22:13524585251380003. doi: 10.1177/13524585251380003.
    >> Share

  109. CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
    Response to the letter by Uysal Tan and Tan regarding our article "short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis".
    Mult Scler. 2025 Sep 22:13524585251380411. doi: 10.1177/13524585251380411.
    >> Share

  110. SHIPLEY J, Beadnall HN, Sanfilippo PG, Horakova D, et al
    Disease course after pregnancy in women with progressive multiple sclerosis symptoms.
    Mult Scler. 2025 Sep 20:13524585251368248. doi: 10.1177/13524585251368248.
    >> Share

  111. SALAZAR-CAMELO A, Vega L, Fadlallah Y, Bou Rjeily N, et al
    Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls.
    Mult Scler. 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350.
    >> Share

  112. GERNERT JA, Klein M, Schoberl F, Muller KJ, et al
    Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab.
    Mult Scler. 2025 Sep 11:13524585251369425. doi: 10.1177/13524585251369425.
    >> Share

  113. TOUBASI A, Hett K, Xu J, Gheen C, et al
    Parasagittal dural space and arachnoid granulations morphology in pre-clinical and early clinical multiple sclerosis.
    Mult Scler. 2025 Sep 10:13524585251364720. doi: 10.1177/13524585251364720.
    >> Share

  114. PONZANO M, Fedriga MM, Signori A, Bergamaschi R, et al
    Social determinants of health in multiple sclerosis in Italy: A scoping review.
    Mult Scler. 2025 Sep 10:13524585251353196. doi: 10.1177/13524585251353196.
    >> Share

  115. ZHAO-FLEMING HH, Decker PA, Kosel ML, Drucker KL, et al
    Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination.
    Mult Scler. 2025 Sep 8:13524585251371984. doi: 10.1177/13524585251371984.
    >> Share

  116. LARONI A, Vigo T, Inglese M, Uccelli A, et al
    Immunosenescence in multiple sclerosis: New insights and clinical implications.
    Mult Scler. 2025 Sep 2:13524585251367611. doi: 10.1177/13524585251367611.
    >> Share

  117. LI J, Hutton GJ, Aparasu RR
    Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021.
    Mult Scler. 2025 Sep 2:13524585251368687. doi: 10.1177/13524585251368687.
    >> Share

  118. TOUBASI AA, Graham M, Cutter G, Gheen C, et al
    Comparing the macromolecular-to-free pool size ratio and the magnetization transfer ratio for the assessment of myelin injury in early multiple sclerosis.
    Mult Scler. 2025 Sep 1:13524585251364766. doi: 10.1177/13524585251364766.
    >> Share

  119. KOUKOU G, Bartels F, Aigner A, Cleaveland R, et al
    Reduced brain volumes in children with radiologically isolated syndrome.
    Mult Scler. 2025;31:1195-1204.
    >> Share

    August 2025
  120. BRUNO A, Greco R
    Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? No.
    Mult Scler. 2025 Aug 29:13524585251364144. doi: 10.1177/13524585251364144.
    >> Share

  121. MASSEY J, Monif M
    Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Commentary.
    Mult Scler. 2025 Aug 29:13524585251370085. doi: 10.1177/13524585251370085.
    >> Share

  122. DERSCH R, Wiendl H
    'Anti-B cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation': Yes.
    Mult Scler. 2025 Aug 29:13524585251364140. doi: 10.1177/13524585251364140.
    >> Share

  123. BRIGGS FB, Genuario I, De Nadai AS, Gunzler DD, et al
    Predicting suicidal ideation at subsequent clinical encounter in multiple sclerosis patients.
    Mult Scler. 2025 Aug 25:13524585251365207. doi: 10.1177/13524585251365207.
    >> Share

  124. ZHAO DH, Hadley G, Pisa M, Saunders P, et al
    Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage.
    Mult Scler. 2025 Aug 20:13524585251365791. doi: 10.1177/13524585251365791.
    >> Share

  125. KRAJNC N, Ponleitner M, Fottinger F, Leutmezer F, et al
    Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis.
    Mult Scler. 2025 Aug 19:13524585251360972. doi: 10.1177/13524585251360972.
    >> Share

  126. KRAUSE N, Derad C, von Glasenapp B, Riemann-Lorenz K, et al
    Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis - Results of the randomised controlled POWER@MS1 trial.
    Mult Scler. 2025 Aug 12:13524585251356410. doi: 10.1177/13524585251356410.
    >> Share

  127. JOKUBAITIS VG, Alroughani R, Altintas A, Eichau S, et al
    Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
    Mult Scler. 2025;31:1088-1101.
    >> Share

    July 2025
  128. AXHAUSEN F, Mrochen A, Winter P, Baumgart R, et al
    Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis.
    Mult Scler. 2025 Jul 30:13524585251361330. doi: 10.1177/13524585251361330.
    >> Share

  129. CELLERINO M, Massarotti C, Peluffo C, Sirito T, et al
    Relationship between ovarian reserve and disease activity in women with multiple sclerosis.
    Mult Scler. 2025 Jul 28:13524585251356384. doi: 10.1177/13524585251356384.
    >> Share

  130. ASP AJ, Jahanian O, Gill ML, Veith DD, et al
    Percutaneous epidural spinal cord stimulation immediately reduces clonus in an individual with multiple sclerosis.
    Mult Scler. 2025 Jul 28:13524585251357143. doi: 10.1177/13524585251357143.
    >> Share

  131. FEYS P, Lamers I, Kos D, Reebye R, et al
    Embracing the complexity of rehabilitation in multiple sclerosis empowered by the resolution of the World Health Organization.
    Mult Scler. 2025 Jul 23:13524585251356967. doi: 10.1177/13524585251356967.
    >> Share

  132. COHEN JA, Arnold DL, DeLuca J, Hartung HP, et al
    Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
    Mult Scler. 2025 Jul 23:13524585251355842. doi: 10.1177/13524585251355842.
    >> Share

  133. LEBRUN-FRENAY C, Okuda DT
    High-risk populations should be screened for multiple sclerosis: No.
    Mult Scler. 2025 Jul 8:13524585251353025. doi: 10.1177/13524585251353025.
    >> Share

  134. BECZEK A, Landt EM, Magyari M, Storr LK, et al
    Assessing the association between mortality and clinical follow-up visits in multiple sclerosis.
    Mult Scler. 2025 Jul 7:13524585251353079. doi: 10.1177/13524585251353079.
    >> Share

  135. BOFFA G, Genchi A, Mariottini A, Brittain G, et al
    Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
    Mult Scler. 2025 Jul 7:13524585251349129. doi: 10.1177/13524585251349129.
    >> Share

  136. AFFINITO G, Moccia M, Lanzillo R, Marrie RA, et al
    Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data.
    Mult Scler. 2025 Jul 3:13524585251347513. doi: 10.1177/13524585251347513.
    >> Share

    June 2025
  137. CRUZ RIVERA S, Buxhoeveden S, Aiyegbusi OL, Bozinov N, et al
    The importance of patient-reported outcomes: A call for their integration in the routine care of patients with multiple sclerosis.
    Mult Scler. 2025 Jun 29:13524585251349354. doi: 10.1177/13524585251349354.
    >> Share

  138. BALSHI A, Dempsey JP, Manning N, Leuenberger G, et al
    Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.
    Mult Scler. 2025 Jun 25:13524585251342725. doi: 10.1177/13524585251342725.
    >> Share

  139. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis.
    Mult Scler. 2025 Jun 19:13524585251345317. doi: 10.1177/13524585251345317.
    >> Share

  140. ARAB BAFRANI M, Rios V, Kim MJ, Balan A, et al
    Gynecological health: A missing link in comprehensive treatment monitoring for multiple sclerosis.
    Mult Scler. 2025 Jun 18:13524585251346371. doi: 10.1177/13524585251346371.
    >> Share

  141. SAHU M, Chomba M, Mortel D, Braun S, et al
    Factors associated with delay to diagnosis of multiple sclerosis in Zambia.
    Mult Scler. 2025 Jun 17:13524585251344832. doi: 10.1177/13524585251344832.
    >> Share

  142. BEREK K, Schmidauer M, Bsteh G, Auer M, et al
    Kappa free light chain index predicts long-term disease activity and disability accrual in multiple sclerosis.
    Mult Scler. 2025 Jun 16:13524585251344807. doi: 10.1177/13524585251344807.
    >> Share

  143. STEIN C, O'Keeffe F, Brosnan M, Flynn C, et al
    Cognitive reserve in multiple sclerosis: The role of depression and fatigue.
    Mult Scler. 2025 Jun 11:13524585251338757. doi: 10.1177/13524585251338757.
    >> Share

  144. MOCCIA M
    Clinical commentary to gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341177. doi: 10.1177/13524585251341177.
    >> Share

  145. NEYAL N, Nathoo N, Cathcart-Rake EJ, Kantarci OH, et al
    Gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341174. doi: 10.1177/13524585251341174.
    >> Share

  146. VARLEY J, Beyrouti R, Nicholas R, Dorsey R, et al
    A comparison of JC virus assay performance provided with originator and biosimilar natalizumab.
    Mult Scler. 2025;31:882-885.
    >> Share

  147. VUKUSIC S, Hubben F, Gavoille A, Malek Y, et al
    Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?
    Mult Scler. 2025;31:877-881.
    >> Share

  148. GARTHOF S, Schafer S, Elmers J, Schwed L, et al
    Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.
    Mult Scler. 2025;31:856-865.
    >> Share

  149. LEAVITT VM, Fox R, Mostert J, D'Haeseleer M, et al
    Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study.
    Mult Scler. 2025;31:866-876.
    >> Share

  150. ARNOLD DL, Kolind S, Assemlal HE, Bar-Or A, et al
    Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.
    Mult Scler. 2025;31:821-832.
    >> Share

    May 2025
  151. NOVAKOVA L, Rosenstein I, Axelsson M, Schoonheim MM, et al
    Plateau of practice effects and noise with repeat SDMT testing and in multiple sclerosis.
    Mult Scler. 2025 May 31:13524585251344794. doi: 10.1177/13524585251344794.
    >> Share

  152. VILASECA A, Vidal-Jordana A, Sceppacuercia S, Calderon W, et al
    Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?
    Mult Scler. 2025 May 30:13524585251332115. doi: 10.1177/13524585251332115.
    >> Share

  153. FOONG YC, Butzkueven H
    Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? - No.
    Mult Scler. 2025 May 26:13524585251344805. doi: 10.1177/13524585251344805.
    >> Share

  154. ROD BE, Hogestol EA, Torkildsen O, Bjornevik K, et al
    Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.
    Mult Scler. 2025 May 26:13524585251342727. doi: 10.1177/13524585251342727.
    >> Share

  155. ROSTON S, Quick MH, Tisavipat N, Rattanathamsakul N, et al
    Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.
    Mult Scler. 2025 May 26:13524585251340841. doi: 10.1177/13524585251340841.
    >> Share

  156. ZANE GK, Sutton A, Brumwell A, Hossain MR, et al
    The path to prevention of multiple sclerosis: Considerations for Epstein-Barr virus vaccine-based prevention studies.
    Mult Scler. 2025 May 26:13524585251340812. doi: 10.1177/13524585251340812.
    >> Share

  157. MARRIE RA, Maxwell CJ, Everett K, Zhu F, et al
    Health care use preceding pediatric multiple sclerosis: A population-based study from Ontario, Canada.
    Mult Scler. 2025 May 23:13524585251338745. doi: 10.1177/13524585251338745.
    >> Share

  158. MACCARRONE D, Prados F, Ciccarelli O
    The relationship between cladribine and reduced regional grey matter volume loss in people with relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 May 3:13524585251338772. doi: 10.1177/13524585251338772.
    >> Share

  159. LOREFICE L, Zivadinov R
    Treating comorbidities in multiple sclerosis is disease-modifying: Yes.
    Mult Scler. 2025 May 3:13524585251338750. doi: 10.1177/13524585251338750.
    >> Share

  160. GRESELIN M, Lu PJ, Mroczek M, Cerda-Fuertes N, et al
    AI-assisted identification of disability patterns within identical EDSS grades.
    Mult Scler. 2025;31:677-688.
    >> Share

  161. FOX RJ, Cohan S, Mao-Draayer Y, Weinstock-Guttman B, et al
    Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study.
    Mult Scler. 2025;31:706-718.
    >> Share

    April 2025
  162. YALDIZLI O, Benkert P, Achtnichts L, Bar-Or A, et al
    Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.
    Mult Scler. 2025 Apr 28:13524585251335466. doi: 10.1177/13524585251335466.
    >> Share

  163. STEPHENS S, Iseyas N, Yeh EA
    Physical activity demonstrates protective associations with structural visual metrics in children with multiple sclerosis through time.
    Mult Scler. 2025 Apr 28:13524585251335510. doi: 10.1177/13524585251335510.
    >> Share

  164. PILOTTO S, Pontieri L, Nielsen HH, Rasmussen PV, et al
    Pediatric Onset Multiple Sclerosis (POMS): Exploring phenotypic characterization and pubertal influences in modulating the disease activity from the Danish MS Registry (DMSR).
    Mult Scler. 2025 Apr 28:13524585251335476. doi: 10.1177/13524585251335476.
    >> Share

  165. MADILL E, Moreira Ferreira V, Healy B, Zurawski J, et al
    Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis.
    Mult Scler. 2025 Apr 28:13524585251335521. doi: 10.1177/13524585251335521.
    >> Share

  166. FERRAZZANO G, Maccarrone D, Guerra A, Collura A, et al
    The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A randomized, double-blind, sham-controlled, pilot study.
    Mult Scler. 2025 Apr 26:13524585251333575. doi: 10.1177/13524585251333575.
    >> Share

  167. GREENWALD MA, Cancel Asencio HG, Dwyer J, Moss A, et al
    Differential Validity in the Written, Oral, and Electronic SDMT in Multiple Sclerosis.
    Mult Scler. 2025 Apr 24:13524585251330961. doi: 10.1177/13524585251330961.
    >> Share

  168. KRAJNC N, Fottinger F, Ponleitner M, Kornek B, et al
    Diagnostic accuracy of inter-eye difference of ganglion cell layer alone in identifying optic neuritis in multiple sclerosis.
    Mult Scler. 2025 Apr 22:13524585251332895. doi: 10.1177/13524585251332895.
    >> Share

  169. MARRIE RA, Bolton JM, Ling V, Bernstein CN, et al
    Risk factors for incident peripartum mental illness in multiple sclerosis.
    Mult Scler. 2025 Apr 18:13524585251330109. doi: 10.1177/13524585251330109.
    >> Share

  170. MACARON G, Farah N, Charbonneau S, Morrow SA, et al
    Addressing patient-reported cognitive impairment in multiple sclerosis clinical practice: A challenging endeavor.
    Mult Scler. 2025 Apr 18:13524585251334488. doi: 10.1177/13524585251334488.
    >> Share

  171. FADLALLAH Y, Wang Y, Malik MT, Tian F, et al
    Frequency and potential risk factors associated with the development of asymptomatic T2 hyperintense cervical spine lesions on MRI in patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 Apr 17:13524585251331405. doi: 10.1177/13524585251331405.
    >> Share

  172. JENSEN MP, Robles S, Nash MG, May S, et al
    Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study.
    Mult Scler. 2025 Apr 17:13524585251329820. doi: 10.1177/13524585251329820.
    >> Share

  173. EL AYOUBI NK, Bal MN, Metri N, El Sammak S, et al
    Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study.
    Mult Scler. 2025 Apr 12:13524585251332499. doi: 10.1177/13524585251332499.
    >> Share

  174. BSTEH G, Hegen H, Albrecht P, Havla J, et al
    Emphasizing complementary in "Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis".
    Mult Scler. 2025 Apr 12:13524585251329800. doi: 10.1177/13524585251329800.
    >> Share

  175. CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
    Response to letter to the editor: 'Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis'.
    Mult Scler. 2025 Apr 12:13524585251329787. doi: 10.1177/13524585251329787.
    >> Share

  176. LIU X, Wang Y, Wei N, Zhu W, et al
    The characteristics and influencing factors of paramagnetic rim lesions in Chinese MS patients: A 7T MRI study.
    Mult Scler. 2025 Apr 12:13524585251328902. doi: 10.1177/13524585251328902.
    >> Share

  177. REVIE L, Jurjens A, Eveslage M, Trumpelmann S, et al
    Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab.
    Mult Scler. 2025 Apr 3:13524585251329849. doi: 10.1177/13524585251329849.
    >> Share

  178. SAYLOR D, Rijke N, McDonell J, Laurson-Doube J, et al
    Recommendations for essential medicines for multiple sclerosis in low-resource settings.
    Mult Scler. 2025;31:464-473.
    >> Share

  179. MERLO D, Ja J, Foong YC, Zhu C, et al
    Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis.
    Mult Scler. 2025 Apr 1:13524585251329035. doi: 10.1177/13524585251329035.
    >> Share

  180. BARANZINI SE
    The Barancik award lecture: Multi-disciplinary research will be the key to stop, restore, and end MS.
    Mult Scler. 2025;31:384-391.
    >> Share

  181. BOBELNA B, Lobjois Q, Croitoru S, Jalkh E, et al
    Incidence of optic neuritis among Afro-descendant, a cohort study.
    Mult Scler. 2025;31:529-538.
    >> Share

  182. LAAKSO SM, Oh J, Raufdeen F, Jones A, et al
    Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort.
    Mult Scler. 2025;31:607-611.
    >> Share

    March 2025
  183. CIAMPI E, Garcia L, Carcamo C, Soler B, et al
    Practical issues concerning the use of optical coherence tomography in multiple sclerosis in Latin America: Discussion from 19 centres on behalf of the Foro Latam EM study group.
    Mult Scler. 2025 Mar 29:13524585251329159. doi: 10.1177/13524585251329159.
    >> Share

  184. LEVIT E, Cohen I, Mahajan A, Ulano A, et al
    Evaluation of the relationship between brainstem lesions and apnea hypopnea index in patients with multiple sclerosis.
    Mult Scler. 2025 Mar 29:13524585251327875. doi: 10.1177/13524585251327875.
    >> Share

  185. NOROOZI R, Tsai HH, Yu K, Bronson P, et al
    Metabolic and lipid alterations in multiple sclerosis linked to disease severity.
    Mult Scler. 2025 Mar 27:13524585251325468. doi: 10.1177/13524585251325468.
    >> Share

  186. LIU X, Zhang C
    Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Mar 27:13524585251324854. doi: 10.1177/13524585251324854.
    >> Share

  187. SIMANI L, Leavitt VM
    Response to the letter: Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Mar 27:13524585251324872. doi: 10.1177/13524585251324872.
    >> Share

  188. BAKIRTZIS C, Dimitriou N, Moysiadis T, El-Wahsh S, et al
    Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status.
    Mult Scler. 2025 Mar 20:13524585251328556. doi: 10.1177/13524585251328556.
    >> Share

  189. FREEDMAN DE, Oh J, Meza C, Feinstein A, et al
    Seizure history and cognitive dysfunction in people with multiple sclerosis.
    Mult Scler. 2025 Mar 18:13524585251326841. doi: 10.1177/13524585251326841.
    >> Share

  190. WILLIAMS J, Marin WM, Wade KJ, Suseno R, et al
    Copy number variation at the complement C4 locus is associated with risk for multiple sclerosis.
    Mult Scler. 2025 Mar 15:13524585251324850. doi: 10.1177/13524585251324850.
    >> Share

  191. CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
    Short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis.
    Mult Scler. 2025 Mar 13:13524585251323178. doi: 10.1177/13524585251323178.
    >> Share

  192. CARVAJAL R, Tur C, Borras-Bermejo B, Saylor D, et al
    Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization.
    Mult Scler. 2025 Mar 12:13524585251318513. doi: 10.1177/13524585251318513.
    >> Share

  193. MAILLART E, Rollot F, Leray E, Benyahya L, et al
    Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population.
    Mult Scler. 2025;31:324-337.
    >> Share

  194. ZEYDAN B, Son J, Neyal N, Schwarz CG, et al
    Upper cervical spinal cord atrophy in MS: Sex, menopause, and neurodegeneration.
    Mult Scler. 2025;31:278-289.
    >> Share

  195. LEBRUN-FRENAY C
    The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives.
    Mult Scler. 2025;31:249-256.
    >> Share

  196. AL GBURI M, Mazzola M, Absinta M, Gaitan MI, et al
    Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter.
    Mult Scler. 2025;31:263-277.
    >> Share

  197. RAMDANI R, Pique J, Deschamps R, Ciron J, et al
    Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study.
    Mult Scler. 2025;31:290-302.
    >> Share

    February 2025
  198. STOGBAUER J, Schegerer V, Berger FK, Schulz-Schaeffer W, et al
    Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report.
    Mult Scler. 2025 Feb 27:13524585251322327. doi: 10.1177/13524585251322327.
    >> Share

  199. BALSHI A
    Climate change and multiple sclerosis: Clinical challenges and strategies.
    Mult Scler. 2025 Feb 26:13524585251322664. doi: 10.1177/13524585251322664.
    >> Share

  200. GOGA JJ, Ginell KM, Ng YT, Ehde DM, et al
    Feasibility, reliability, and validity of ambulatory smartphone-administered cognitive tests in multiple sclerosis.
    Mult Scler. 2025 Feb 25:13524585251320814. doi: 10.1177/13524585251320814.
    >> Share

  201. BARRANTES-CEPAS M, Noteboom S, Colato E, Battaglini M, et al
    Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.
    Mult Scler. 2025 Feb 25:13524585251314779. doi: 10.1177/13524585251314779.
    >> Share

  202. DELUCA J
    An interdisciplinary approach is necessary in the treatment of cognitive decline in Multiple Sclerosis: Commentary.
    Mult Scler. 2025 Feb 25:13524585251315357. doi: 10.1177/13524585251315357.
    >> Share

  203. DONKERS SJ, Walker LA
    An interdisciplinary approach is necessary in the treatment of cognitive decline in multiple sclerosis - YES.
    Mult Scler. 2025 Feb 25:13524585251315344. doi: 10.1177/13524585251315344.
    >> Share

  204. SCHOEPS VA, Smith JB, Langer-Gould A
    Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility.
    Mult Scler. 2025 Feb 19:13524585251318293. doi: 10.1177/13524585251318293.
    >> Share

  205. LINDBERG S, Sandgren S, Axelsson M, Rosenstein I, et al
    Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.
    Mult Scler. 2025 Feb 18:13524585251318516. doi: 10.1177/13524585251318516.
    >> Share

  206. KARATSIDIS A, Angelini L, Scaramozza M, Bartholome E, et al
    Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework.
    Mult Scler. 2025 Feb 18:13524585251316242. doi: 10.1177/13524585251316242.
    >> Share

  207. MITRACHE DESAGA AC, Noui Y, Silfverberg T, Carlson K, et al
    Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2025 Feb 17:13524585251315363. doi: 10.1177/13524585251315363.
    >> Share

  208. SIMONSEN CS, Flemmen HO, Broch L, Brekke K, et al
    Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.
    Mult Scler. 2025 Feb 17:13524585251315077. doi: 10.1177/13524585251315077.
    >> Share

  209. VAVASOUR I, Elliott C, Arnold DL, Gaetano L, et al
    Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time.
    Mult Scler. 2025 Feb 14:13524585251316519. doi: 10.1177/13524585251316519.
    >> Share

  210. ALBERGONI M, Preziosa P, Meani A, Dallari C, et al
    Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients.
    Mult Scler. 2025 Feb 14:13524585251318647. doi: 10.1177/13524585251318647.
    >> Share

  211. MARRODAN M, Sao Aviles A, Rio J, Cobo-Calvo A, et al
    Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.
    Mult Scler. 2025 Feb 10:13524585251316471. doi: 10.1177/13524585251316471.
    >> Share

  212. VILASECA A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, et al
    Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.
    Mult Scler. 2025 Feb 5:13524585251314749. doi: 10.1177/13524585251314749.
    >> Share

  213. SUMOWSKI JF, Sandry J
    Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty.
    Mult Scler. 2025 Feb 2:13524585241309805. doi: 10.1177/13524585241309805.
    >> Share

  214. TAUL-MADSEN L, Hvid LG, Riis H, Brolos MK, et al
    A head-to-head comparison of the effects of aerobic versus resistance training on physical capacity and physical function in people with multiple sclerosis: Results from the MSBOOST trial.
    Mult Scler. 2025;31:174-183.
    >> Share

  215. CORBOY JR, Fox RJ, Cutter G, Engebretson E, et al
    DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
    Mult Scler. 2025;31:159-173.
    >> Share

  216. LEBRUN-FRENAY C, Kerbrat S, Okuda DT, Landes-Chateau C, et al
    Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome.
    Mult Scler. 2025;31:184-196.
    >> Share

  217. PATEL AD, Connors A, Esch ME
    Ofatumumab-associated colitis: A case report.
    Mult Scler. 2025;31:242-245.
    >> Share

    January 2025
  218. MARTIRE MS, Moiola L, Maggi P, Borrelli S, et al
    Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple sclerosis patients.
    Mult Scler. 2025 Jan 31:13524585251314358. doi: 10.1177/13524585251314358.
    >> Share

  219. ACHIRON A, Warszawer Y, Nissan Y, Kerpel A, et al
    Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study.
    Mult Scler. 2025 Jan 27:13524585251313749. doi: 10.1177/13524585251313749.
    >> Share

  220. DE ANGELIS F, Ammoscato F, Parker RA, Plantone D, et al
    Neurofilament heavy chain in secondary progressive multiple sclerosis.
    Mult Scler. 2025 Jan 22:13524585241311212. doi: 10.1177/13524585241311212.
    >> Share

  221. YILMAZER C, D'haeseleer M, Soler B, Van Wijmeersch B, et al
    Assessing pain in multiple sclerosis: Test-retest reliability of patient-reported outcome measures and accuracy of screening tools.
    Mult Scler. 2025 Jan 16:13524585241310139. doi: 10.1177/13524585241310139.
    >> Share

  222. DEL CANTO A, Carcamo C, Garcia L, Aylwin E, et al
    Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis.
    Mult Scler. 2025 Jan 6:13524585241309835. doi: 10.1177/13524585241309835.
    >> Share

  223. WITT L, Dost-Kovalsky K, Friedmann N, Bast N, et al
    Ofatumumab-exposed breastfeeding in multiple sclerosis patients.
    Mult Scler. 2025 Jan 6:13524585241307165. doi: 10.1177/13524585241307165.
    >> Share

  224. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis.
    Mult Scler. 2025 Jan 3:13524585241310104. doi: 10.1177/13524585241310104.
    >> Share

  225. SIMANI L, Tozlu C, Lee S, Dworkin J, et al
    Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Jan 3:13524585241303491. doi: 10.1177/13524585241303491.
    >> Share

  226. GIOVANNONI G, Boyko A, Correale J, Edan G, et al
    Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
    Mult Scler. 2025;31:44-58.
    >> Share

  227. MANISCALCO GT, Dinoto A, Foglia MC, Di Battista ME, et al
    Epstein-Barr virus infection in patients with MOGAD.
    Mult Scler. 2025;31:117-120.
    >> Share

    December 2024
  228. MAGGI G, Altieri M, Risi M, Rippa V, et al
    Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Dec 27:13524585241302167. doi: 10.1177/13524585241302167.
    >> Share

  229. BRIGGS FB, Conway DS, Hersh CM, Fitzgerald KC, et al
    The onset presentation of multiple sclerosis differs in Hispanic/Latinx Americans compared with non-Hispanic White Americans.
    Mult Scler. 2024 Dec 24:13524585241304976. doi: 10.1177/13524585241304976.
    >> Share

  230. CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
    Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Dec 20:13524585241304356. doi: 10.1177/13524585241304356.
    >> Share

  231. MALLUCCI G, Zimmer A, Sfikas N, Cerda-Fuertes N, et al
    Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.
    Mult Scler. 2024 Dec 20:13524585241305966. doi: 10.1177/13524585241305966.
    >> Share

  232. CORREALE J, Marrodan M
    Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision.
    Mult Scler. 2024 Dec 18:13524585241305956. doi: 10.1177/13524585241305956.
    >> Share

  233. NYLANDER A, Sisodia N, Henderson K, Wijangco J, et al
    From "invisible" to "audible": Features extracted during simple speech tasks classify patient-reported fatigue in multiple sclerosis.
    Mult Scler. 2024 Dec 17:13524585241303855. doi: 10.1177/13524585241303855.
    >> Share

  234. VAN DAM M, Rottgering JG, Nauta IM, de Jong BA, et al
    Understanding the complex network of objectively assessed cognition and self-reported psychological symptoms in people with multiple sclerosis.
    Mult Scler. 2024 Dec 9:13524585241302173. doi: 10.1177/13524585241302173.
    >> Share

  235. KRYSKO KM
    Considerations for family planning in adolescent and young adults with multiple sclerosis.
    Mult Scler. 2024 Dec 7:13524585241303481. doi: 10.1177/13524585241303481.
    >> Share

  236. CHANG G, Stoney S, Narula S
    Pregnancy outcomes in adolescent and young adult patients with multiple sclerosis: A case series.
    Mult Scler. 2024 Dec 7:13524585241303490. doi: 10.1177/13524585241303490.
    >> Share

  237. FRAMKE E, Sellebjerg F, Kant M, Stilund M, et al
    Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.
    Mult Scler. 2024 Dec 4:13524585241299715. doi: 10.1177/13524585241299715.
    >> Share

  238. JIANG X, McGinley M, Johnston J, Alberts J, et al
    A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosis.
    Mult Scler. 2024 Dec 1:13524585241301854. doi: 10.1177/13524585241301854.
    >> Share

  239. CHITNIS T, Arnold DL, Quartier P, Chirieac M, et al
    Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study.
    Mult Scler. 2024 Dec 1:13524585241295554. doi: 10.1177/13524585241295554.
    >> Share

  240. PORTACCIO E
    Toward a holistic approach to multiple sclerosis: The role of social determinants of health.
    Mult Scler. 2024 Dec 1:13524585241302684. doi: 10.1177/13524585241302684.
    >> Share

  241. LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
    Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
    Mult Scler. 2024 Dec 1:13524585241289276. doi: 10.1177/13524585241289276.
    >> Share

  242. CARVAJAL R, Rodriguez-Acevedo B, Garcia-Vasco L, Zabalza A, et al
    Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.
    Mult Scler. 2024;30:1788-1801.
    >> Share

  243. KEVER A, Heuer LB, Simani L, Leavitt VM, et al
    Development and initial validation of the Cognitive Change Scale (CCS).
    Mult Scler. 2024;30:1815-1824.
    >> Share

  244. GAITAN MI, Marquez RV, Ayerbe J, Reich DS, et al
    Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.
    Mult Scler. 2024;30.
    >> Share

  245. MOTL RW
    Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs.
    Mult Scler. 2024;30.
    >> Share

  246. PILUTTI LA, Donkers SJ
    Exercise as a Therapeutic Intervention in Multiple Sclerosis.
    Mult Scler. 2024;30.
    >> Share

  247. MCGINLEY MP
    Improving Access to MS Care Through Technology.
    Mult Scler. 2024;30.
    >> Share

  248. BERGSLAND N, Dwyer MG, Zivadinov R
    Imaging the Choroid Plexus.
    Mult Scler. 2024;30.
    >> Share

  249. LANGER-GOULD A
    Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: No.
    Mult Scler. 2024;30.
    >> Share

  250. ONTANEDA D, Miron VE
    Breaking Barriers in Multiple Sclerosis.
    Mult Scler. 2024;30.
    >> Share

  251. KOCH MW, Camara-Lemarroy C, Strijbis E, Mostert J, et al
    Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.
    Mult Scler. 2024;30.
    >> Share

    November 2024
  252. LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
    Association between education level and disability progression in patients with multiple sclerosis in France.
    Mult Scler. 2024 Nov 30:13524585241289274. doi: 10.1177/13524585241289274.
    >> Share

  253. KALAITZIDIS G, Ezzedin O, Bacchetti A, Moussa H, et al
    Homonymous hemi-macular atrophy in multiple sclerosis.
    Mult Scler. 2024 Nov 23:13524585241297816. doi: 10.1177/13524585241297816.
    >> Share

  254. GANS A, Verrengia EP, Ricchiuti E, Leva S, et al
    Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review.
    Mult Scler. 2024 Nov 21:13524585241295677. doi: 10.1177/13524585241295677.
    >> Share

  255. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
    Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study.
    Mult Scler. 2024 Nov 14:13524585241297003. doi: 10.1177/13524585241297003.
    >> Share

  256. MAGGI P, Absinta M
    Emerging MRI biomarkers for the diagnosis of multiple sclerosis.
    Mult Scler. 2024 Nov 7:13524585241293579. doi: 10.1177/13524585241293579.
    >> Share

  257. HOFFMAN EM, Brown L, Jolliffe E, Sechi E, et al
    McArdle sign and neck flexion-induced change in central motor conduction in multiple sclerosis.
    Mult Scler. 2024 Nov 6:13524585241295868. doi: 10.1177/13524585241295868.
    >> Share

  258. WITT L, Haben S, Dost-Kovalsky K, Friedmann N, et al
    Impact of symptomatic multiple sclerosis therapy on pregnancy outcome.
    Mult Scler. 2024 Nov 6:13524585241293363. doi: 10.1177/13524585241293363.
    >> Share

  259. HOCHSTETLER A, Lehtinen MK
    Choroid plexus as a mediator of CNS inflammation in multiple sclerosis.
    Mult Scler. 2024 Nov 6:13524585241292974. doi: 10.1177/13524585241292974.
    >> Share

  260. JIANG Y, Cesta CE, Liu Q, Kingwell E, et al
    Exploring the relationship between polycystic ovarian syndrome, testosterone, and multiple sclerosis in women: A nationwide cohort study and genome-wide cross-trait analysis.
    Mult Scler. 2024 Nov 6:13524585241292802. doi: 10.1177/13524585241292802.
    >> Share

  261. TOOROP AA, Wessels MH, Boonkamp L, Gelissen LM, et al
    Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
    Mult Scler. 2024 Nov 4:13524585241293940. doi: 10.1177/13524585241293940.
    >> Share

  262. HSU S, Balan A, Bove R
    Topical review: Lactation and use of DMTs in women with MS.
    Mult Scler. 2024;30:1578-1591.
    >> Share

    October 2024
  263. YOUNG CA, Rog DJ, Sharrack B, Tanasescu R, et al
    Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29).
    Mult Scler. 2024 Oct 30:13524585241288393. doi: 10.1177/13524585241288393.
    >> Share

  264. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
    Phenotyping in vivo chronic inflammation in multiple sclerosis by combined (11)C-PBR28 MR-PET and 7T susceptibility-weighted imaging.
    Mult Scler. 2024 Oct 22:13524585241284157. doi: 10.1177/13524585241284157.
    >> Share


  265. Erratum to "Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis" Multiple Sclerosis Journal; 2024: 30(8); 1086-1088. DOI: 10.1177/13524585241260564.
    Mult Scler. 2024 Oct 22:13524585241290986. doi: 10.1177/13524585241290986.
    >> Share

  266. PALLADINO R, Chataway J, Mathew M, Majeed A, et al
    Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.
    Mult Scler. 2024 Oct 17:13524585241287388. doi: 10.1177/13524585241287388.
    >> Share

  267. DE NADAI AS, Zamora RJ, Finch A, Miller DM, et al
    Multiple sclerosis subgroups: Data-driven clusters based on patient-reported outcomes and a large clinical sample.
    Mult Scler. 2024 Oct 17:13524585241282763. doi: 10.1177/13524585241282763.
    >> Share

  268. VAN LIEROP ZY, Wessels MH, Lekranty WM, Moraal B, et al
    Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.
    Mult Scler. 2024 Oct 17:13524585241277044. doi: 10.1177/13524585241277044.
    >> Share

  269. VLAD B, Neidhart S, Hilty M, Asplund Hogelin K, et al
    Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.
    Mult Scler. 2024 Oct 8:13524585241279645. doi: 10.1177/13524585241279645.
    >> Share

  270. AMEZCUA L, Hamilton RH, Ciccarelli O
    The current state of diversity, equity, and inclusion in multiple sclerosis research, clinical trials, and workforce.
    Mult Scler. 2024 Oct 8:13524585241286988. doi: 10.1177/13524585241286988.
    >> Share

  271. VERCELLINO M, Marasciulo S, Ricotti E, Rolando A, et al
    Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis.
    Mult Scler. 2024 Oct 7:13524585241284846. doi: 10.1177/13524585241284846.
    >> Share

    September 2024
  272. NESBITT C, Van Der Walt A, Butzkueven H, Devitt B, et al
    Multiple sclerosis and cancer: Navigating a dual diagnosis.
    Mult Scler. 2024 Sep 30:13524585241274523. doi: 10.1177/13524585241274523.
    >> Share

  273. BAYOUMI A, Hasan KM, Thomas JA, Yazdani A, et al
    Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.
    Mult Scler. 2024 Sep 29:13524585241280842. doi: 10.1177/13524585241280842.
    >> Share

  274. OCAMPO A, Hatami F, Cuklina J, Graham G, et al
    Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.
    Mult Scler. 2024 Sep 28:13524585241275471. doi: 10.1177/13524585241275471.
    >> Share

  275. INOJOSA H, Voigt I, Wenk J, Ferber D, et al
    Integrating large language models in care, research, and education in multiple sclerosis management.
    Mult Scler. 2024 Sep 23:13524585241277376. doi: 10.1177/13524585241277376.
    >> Share

  276. JACOBS BM, Schalk L, Tregaskis-Daniels E, Tank P, et al
    The relationship between ethnicity and multiple sclerosis characteristics in the United Kingdom: A UK MS Register study.
    Mult Scler. 2024 Sep 20:13524585241277018. doi: 10.1177/13524585241277018.
    >> Share

  277. O'DONNELL E, Schuette A, Waltz M, Aaen G, et al
    Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis.
    Mult Scler. 2024 Sep 17:13524585241274580. doi: 10.1177/13524585241274580.
    >> Share

  278. PILLONI G, Lustberg M, Malik M, Feinberg C, et al
    Hand functioning in progressive multiple sclerosis improves with tDCS added to daily exercises: A home-based randomized, double-blinded, sham-controlled clinical trial.
    Mult Scler. 2024 Sep 13:13524585241275013. doi: 10.1177/13524585241275013.
    >> Share

  279. LANDI D, Bartolomeo S, Bovis F, Amato MP, et al
    Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy.
    Mult Scler. 2024 Sep 12:13524585241274600. doi: 10.1177/13524585241274600.
    >> Share

  280. HOLTZER R, Foley FW, Motl RW, Wagshul ME, et al
    Brain hemodynamic responses and fall prediction in older adults with multiple sclerosis.
    Mult Scler. 2024 Sep 11:13524585241277400. doi: 10.1177/13524585241277400.
    >> Share

  281. PIEDRABUENA MA, Correale J, Farez MF, Rodriguez Murua S, et al
    Telomere length as a biomarker in multiple sclerosis.
    Mult Scler. 2024 Sep 9:13524585241273054. doi: 10.1177/13524585241273054.
    >> Share

  282. LUNEMANN JD, Sao Aviles A, Tintore M, Midaglia L, et al
    Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset.
    Mult Scler. 2024 Sep 9:13524585241274571. doi: 10.1177/13524585241274571.
    >> Share

  283. ZURRER WE, Cannon AE, Ilchenko D, Gaitan MI, et al
    Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis.
    Mult Scler. 2024 Sep 8:13524585241274527. doi: 10.1177/13524585241274527.
    >> Share

  284. SARTHOU A, Chretien P, Giorgi L, Chiron A, et al
    The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis.
    Mult Scler. 2024 Sep 8:13524585241274034. doi: 10.1177/13524585241274034.
    >> Share

  285. COERVER EM, Kacar S, Ciccarelli O, Sormani MP, et al
    Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
    Mult Scler. 2024 Sep 8:13524585241272938. doi: 10.1177/13524585241272938.
    >> Share

  286. BRIGGS FB, Gunzler DD, Miller DM, Ontaneda D, et al
    Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure.
    Mult Scler. 2024 Sep 5:13524585241274607. doi: 10.1177/13524585241274607.
    >> Share

  287. PETRACCA M, Ruggieri S, Nistri R, Tomasso I, et al
    Brain reserve and timing of clinical onset in multiple sclerosis.
    Mult Scler. 2024 Sep 5:13524585241272046. doi: 10.1177/13524585241272046.
    >> Share

  288. TOLJAN K, Daboul L, Raza P, Martin ML, et al
    Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.
    Mult Scler. 2024 Sep 5:13524585241271988. doi: 10.1177/13524585241271988.
    >> Share

  289. LANDES-CHATEAU C, Ricigliano VA, Mondot L, Thouvenot E, et al
    Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome.
    Mult Scler. 2024;30:1278-1289.
    >> Share

  290. CHICO-GARCIA JL, Sainz Amo R, Monreal E, Sainz de la Maza S, et al
    Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.
    Mult Scler. 2024;30:1341-1349.
    >> Share

  291. COBO-CALVO A, Tintore M
    Prioritizing global strategies to cure MS.
    Mult Scler. 2024;30:1239-1241.
    >> Share

  292. KRUPP L, O'Neill KA
    Monitoring cognitive functioning in MS will trigger anxiety in patients: Yes.
    Mult Scler. 2024;30:1252-1254.
    >> Share

  293. KLEIN M
    Monitoring cognitive functioning in MS will trigger anxiety in patients: No.
    Mult Scler. 2024;30:1254-1256.
    >> Share

    August 2024
  294. BEBO BF JR, Banwell BL, Whitacre CC, Coetzee T, et al
    The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.
    Mult Scler. 2024 Aug 30:13524585241266483. doi: 10.1177/13524585241266483.
    >> Share

  295. ZICCARDI S, Guandalini M, Fuchs TA, Calabrese M, et al
    The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now.
    Mult Scler. 2024 Aug 28:13524585241264476. doi: 10.1177/13524585241264476.
    >> Share

  296. FUCHS TA, Schoonheim MM, Zivadinov R, Dwyer MG, et al
    Cognitive progression independent of relapse in multiple sclerosis.
    Mult Scler. 2024 Aug 28:13524585241256540. doi: 10.1177/13524585241256540.
    >> Share

  297. TUR C, Portaccio E
    Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline.
    Mult Scler. 2024 Aug 28:13524585241273037. doi: 10.1177/13524585241273037.
    >> Share

  298. RIVERO-DE-AGUILAR A, Perez-Rios M, Mascarenas-Garcia M, Ruano-Ravina A, et al
    Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals.
    Mult Scler. 2024 Aug 27:13524585241273089. doi: 10.1177/13524585241273089.
    >> Share

  299. CICCARESE G, Zanghi A, Herzum A, Fidanzi C, et al
    Acute urticaria following ofatumumab injection for multiple sclerosis.
    Mult Scler. 2024 Aug 26:13524585241273084. doi: 10.1177/13524585241273084.
    >> Share

  300. HARROUD A, Sawcer SJ, Baranzini SE
    Genetics of multiple sclerosis severity: The importance of statistical power in replication studies.
    Mult Scler. 2024 Aug 14:13524585241264472. doi: 10.1177/13524585241264472.
    >> Share

  301. MONTOBBIO N, Carmisciano L, Signori A, Ponzano M, et al
    Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis.
    Mult Scler. 2024 Aug 14:13524585241243157. doi: 10.1177/13524585241243157.
    >> Share

  302. KALINCIK T
    The era of harmonised disability outcomes in multiple sclerosis.
    Mult Scler. 2024 Aug 14:13524585241266517. doi: 10.1177/13524585241266517.
    >> Share

  303. CAMPAGNA MP, Lechner-Scott J, Taylor BV, Havrdova EK, et al
    Re: Genetics of multiple sclerosis severity: The importance of statistical power in replication studies and Re: From discovery to replication: Power and definitions matter for multiple sclerosis severity.
    Mult Scler. 2024 Aug 14:13524585241264469. doi: 10.1177/13524585241264469.
    >> Share

  304. LAPUCCI C, Frau J, Cocco E, Coghe G, et al
    Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
    Mult Scler. 2024 Aug 14:13524585241266509. doi: 10.1177/13524585241266509.
    >> Share

  305. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
    Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
    Mult Scler. 2024 Aug 7:13524585241267257. doi: 10.1177/13524585241267257.
    >> Share

  306. CAMPBELL JA, Simpson-Yap S, Taylor BV, van der Mei I, et al
    Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021.
    Mult Scler. 2024 Aug 5:13524585241265890. doi: 10.1177/13524585241265890.
    >> Share

  307. CAMERON MH, Hildebrand A, Hugos C, Wooliscroft L, et al
    A walking aid selection, training, and education program (ADSTEP) to prevent falls in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2024 Aug 5:13524585241265031. doi: 10.1177/13524585241265031.
    >> Share

  308. DVORAK E, Levy S, Anderson JR, Sumowski JF, et al
    Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis.
    Mult Scler. 2024 Aug 5:13524585241259648. doi: 10.1177/13524585241259648.
    >> Share

  309. ROOS I, Sharmin S, Malpas C, Ozakbas S, et al
    Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Aug 1:13524585241267211. doi: 10.1177/13524585241267211.
    >> Share

  310. VOSKUHL R
    All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Yes.
    Mult Scler. 2024;30:1107-1109.
    >> Share

  311. ZHANG Q, Noyce AJ, Robson J, Giovannoni G, et al
    No association between oral contraceptive exposure and subsequent MS: A population-based nested case-control study in primary care.
    Mult Scler. 2024;30:1221-1226.
    >> Share

  312. CHEEMA S, Matharu M
    Facial pain in MS: When to think of trigeminal autonomic cephalalgia.
    Mult Scler. 2024;30:1230-1231.
    >> Share

    July 2024
  313. BEBO B, Coetzee T, Gray E, Helme A, et al
    The first global landscape analysis of multiple sclerosis research funding.
    Mult Scler. 2024 Jul 31:13524585241265961. doi: 10.1177/13524585241265961.
    >> Share

  314. PROSPERINI L, Ruggieri S, Haggiag S, Tortorella C, et al
    Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context.
    Mult Scler. 2024 Jul 31:13524585241266180. doi: 10.1177/13524585241266180.
    >> Share

  315. SIDHU NK, Proudfoot H, Adan HM, Fawson S, et al
    Diversity and inclusion in behavioural intervention trials in multiple sclerosis: A commentary.
    Mult Scler. 2024 Jul 26:13524585241248279. doi: 10.1177/13524585241248279.
    >> Share

  316. STRIDH P, Huang J, Kockum I
    From discovery to replication: Power and definitions matter for multiple sclerosis severity.
    Mult Scler. 2024 Jul 26:13524585241265021. doi: 10.1177/13524585241265021.
    >> Share

  317. MOHAN SD, Peterson S, Brenton JN, Carmichael SL, et al
    Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis.
    Mult Scler. 2024;30:1056-1065.
    >> Share

  318. ZEINEDDINE M, Al-Roughani R, Farouk Ahmed S, Khoury S, et al
    Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
    Mult Scler. 2024;30:1026-1035.
    >> Share

  319. DE JONG DJ, Strijbis EM, Killestein J
    Information from ecological momentary assessments lead to over-medicalization: Commentary.
    Mult Scler. 2024;30:972-973.
    >> Share

  320. PREZIOSA P, Rocca MA, Filippi M
    Information from ecological momentary assessments leads to over-medicalization: No.
    Mult Scler. 2024;30:970-972.
    >> Share

  321. HOGESTOL EA, Berg-Hansen P
    Information from ecological momentary assessments lead to over-medicalization: Yes.
    Mult Scler. 2024;30:968-969.
    >> Share

  322. LEVIT E, Ren Z, Gonzenbach V, Azevedo CJ, et al
    Choroid plexus volume differentiates MS from its mimics.
    Mult Scler. 2024;30:1072-1076.
    >> Share

  323. MEALLI F, Mattei A, Mariottini A, Massacesi L, et al
    Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study.
    Mult Scler. 2024;30:1077-1080.
    >> Share

  324. COBAN H
    Tick-borne illnesses in patients treated with B-cell depleting agents: Considerations for neurologists.
    Mult Scler. 2024;30:1084-1085.
    >> Share

  325. MCMURRAN CE, Mukherjee T, Brown JWL, Coles AJ, et al
    Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.
    Mult Scler. 2024;30:1066-1071.
    >> Share

    June 2024
  326. MOROZUMI T, Preziosa P, Meani A, Pessina G, et al
    Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis.
    Mult Scler. 2024 Jun 24:13524585241260145. doi: 10.1177/13524585241260145.
    >> Share

  327. MALLUCCI G, Monti MC, Ponzio M, Borrelli P, et al
    Impact of multiple sclerosis comorbidities on quality of life and job activity.
    Mult Scler. 2024 Jun 24:13524585241260550. doi: 10.1177/13524585241260550.
    >> Share

  328. SCARAMOZZA M, Chiesa PA, Zajac L, Sun Z, et al
    Konectom cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
    Mult Scler. 2024 Jun 24:13524585241259650. doi: 10.1177/13524585241259650.
    >> Share

  329. MAGYARI M
    All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: No.
    Mult Scler. 2024 Jun 22:13524585241254987. doi: 10.1177/13524585241254987.
    >> Share

  330. PETHERAM K, Dobson R
    All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Commentary.
    Mult Scler. 2024 Jun 22:13524585241254989. doi: 10.1177/13524585241254989.
    >> Share

  331. CONTE WL
    Addressing LGBTQ+ health equity and disparities in multiple sclerosis: A call for research and action.
    Mult Scler. 2024 Jun 19:13524585241263281. doi: 10.1177/13524585241263281.
    >> Share

  332. MORROW SA, Hancock L
    Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in patients: Commentary.
    Mult Scler. 2024 Jun 16:13524585241261200. doi: 10.1177/13524585241261200.
    >> Share

  333. BALSHI A, Manning N, Dempsey J, Kumbar S, et al
    Altered lymphocyte profiles and herpes zoster infections in patients with multiple sclerosis on natalizumab.
    Mult Scler. 2024 Jun 16:13524585241260537. doi: 10.1177/13524585241260537.
    >> Share

  334. KOLSCHE T, Willison AG, Meuth SG, Pawlitzki M, et al
    Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.
    Mult Scler. 2024 Jun 15:13524585241260564. doi: 10.1177/13524585241260564.
    >> Share

  335. DALLA COSTA G, Leocani L, Pisa M, Croese T, et al
    Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.
    Mult Scler. 2024 Jun 14:13524585241260977. doi: 10.1177/13524585241260977.
    >> Share

  336. KRIJNEN EA, Kouwenhoven RM, Noteboom S, Barkhof F, et al
    Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.
    Mult Scler. 2024 Jun 13:13524585241260968. doi: 10.1177/13524585241260968.
    >> Share

  337. SMETS I, Versteegh M, Huygens S, Wokke B, et al
    Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.
    Mult Scler. 2024 Jun 10:13524585241258692. doi: 10.1177/13524585241258692.
    >> Share

  338. NOVA A, Di Caprio G, Bernardinelli L, Fazia T, et al
    Genetic and early life factors influence on time-to-multiple sclerosis diagnosis: A UK Biobank study.
    Mult Scler. 2024 Jun 7:13524585241257205. doi: 10.1177/13524585241257205.
    >> Share

  339. BORRELLI S, Guisset F, Vanden Bulcke C, Stolting A, et al
    Enlarged perivascular spaces are associated with brain microangiopathy and aging in multiple sclerosis.
    Mult Scler. 2024 Jun 7:13524585241256881. doi: 10.1177/13524585241256881.
    >> Share

  340. PONZANO M, Signori A, Bellavia A, Carbone A, et al
    Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review.
    Mult Scler. 2024 Jun 7:13524585241254283. doi: 10.1177/13524585241254283.
    >> Share

  341. FOSTER MA, Prados F, Collorone S, Kanber B, et al
    Improving explanation of motor disability with diffusion-based graph metrics at onset of the first demyelinating event.
    Mult Scler. 2024;30:800-811.
    >> Share

  342. MONTOBBIO N, Bovis F, Signori A, Ponzano M, et al
    Therapeutic lag: Is treatment effect delayed in progressive MS?
    Mult Scler. 2024;30:843-846.
    >> Share

  343. PFEUFFER S
    Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.
    Mult Scler. 2024;30:897-898.
    >> Share

    May 2024
  344. AKBARIAN F, Rossi C, Costers L, D'hooghe MB, et al
    Stimulus-related modulation in the 1/f spectral slope suggests an impaired inhibition during a working memory task in people with multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241253777. doi: 10.1177/13524585241253777.
    >> Share

  345. MENG D, Sacco R, Disanto G, Widmer F, et al
    Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241250199. doi: 10.1177/13524585241250199.
    >> Share

  346. LEBRUN-FRENAY C, Okuda DT
    Time to move past typical syndromes in the diagnosis of multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241253519. doi: 10.1177/13524585241253519.
    >> Share

  347. WICKLEIN R, Kreitner L, Wild A, Aly L, et al
    Retinal small vessel pathology is associated with disease burden in multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241247775. doi: 10.1177/13524585241247775.
    >> Share

  348. NAIZER H, Wozny J, Krause TM, Huson E, et al
    Trends in central nervous system-active polypharmacy among people with multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241251986. doi: 10.1177/13524585241251986.
    >> Share

  349. HEWARD KD, Roy-Hewitson C, Solomon AJ
    Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria.
    Mult Scler. 2024 May 15:13524585241253513. doi: 10.1177/13524585241253513.
    >> Share

  350. COLLORONE S, Coll L, Lorenzi M, Llado X, et al
    Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis.
    Mult Scler. 2024 May 13:13524585241249422. doi: 10.1177/13524585241249422.
    >> Share

  351. DAGNEW B, Laslett LL, Honan CA, Blizzard L, et al
    The association of comorbidities with sleep quality among Australians with multiple sclerosis: Insights from the Australian Multiple Sclerosis Longitudinal Study.
    Mult Scler. 2024 May 13:13524585241248278. doi: 10.1177/13524585241248278.
    >> Share

  352. ANDERSEN ML, Jolving LR, Iachina M, Stenager E, et al
    Children born preterm or small for gestational age to mothers with multiple sclerosis: Do these children have an increased risk of infections in early life?
    Mult Scler. 2024 May 8:13524585241249077. doi: 10.1177/13524585241249077.
    >> Share

  353. PROSPERINI L, Haggiag S
    Late-onset multiple sclerosis from a different angle.
    Mult Scler. 2024 May 8:13524585241249901. doi: 10.1177/13524585241249901.
    >> Share

  354. PORTACCIO E, Grossi P, Bellomi F, Bianchi V, et al
    Meaningful cognitive change for the Minimal Assessment of Cognitive Function in Multiple Sclerosis.
    Mult Scler. 2024 May 8:13524585241249084. doi: 10.1177/13524585241249084.
    >> Share

    April 2024
  355. FEINSTEIN A
    Depression is a core symptom of multiple sclerosis.
    Mult Scler. 2024 Apr 30:13524585241245637. doi: 10.1177/13524585241245637.
    >> Share

  356. HANCOCK LM
    Depression is a core symptom of multiple sclerosis: Yes.
    Mult Scler. 2024 Apr 30:13524585241249564. doi: 10.1177/13524585241249564.
    >> Share

  357. LEAVITT VM
    Depression is a core symptom of multiple sclerosis: NO.
    Mult Scler. 2024 Apr 30:13524585241245653. doi: 10.1177/13524585241245653.
    >> Share

  358. MANUEL AM, Gottlieb A, Freeman L, Zhao Z, et al
    Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data.
    Mult Scler. 2024 Apr 25:13524585241240398. doi: 10.1177/13524585241240398.
    >> Share

  359. BIANCHI A, Cortese R, Prados F, Tur C, et al
    Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease.
    Mult Scler. 2024 Apr 22:13524585241240420. doi: 10.1177/13524585241240420.
    >> Share

  360. NOVAK F, Bajwa HM, Ostergaard K, Berg JM, et al
    Extended interval dosing with ocrelizumab in multiple sclerosis.
    Mult Scler. 2024 Apr 22:13524585241245296. doi: 10.1177/13524585241245296.
    >> Share

  361. OKUDA DT, Lebrun-Frenay C
    Radiologically isolated syndrome in the spectrum of multiple sclerosis.
    Mult Scler. 2024 Apr 15:13524585241245306. doi: 10.1177/13524585241245306.
    >> Share

  362. CHITNIS T, Banwell B, Kappos L, Arnold DL, et al
    Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
    Mult Scler. 2024 Apr 15:13524585241242050. doi: 10.1177/13524585241242050.
    >> Share

  363. HEMOND CC, Solomon AJ
    Multiple sclerosis can be diagnosed solely with dissemination in space: No.
    Mult Scler. 2024 Apr 14:13524585241245297. doi: 10.1177/13524585241245297.
    >> Share

  364. MCGINLEY MP, Cohen JA
    Multiple sclerosis can be diagnosed solely with dissemination in space: Commentary.
    Mult Scler. 2024 Apr 14:13524585241245319. doi: 10.1177/13524585241245319.
    >> Share

  365. TOOSY AT, Barkhof F
    Multiple sclerosis can be diagnosed solely with dissemination in space: Yes.
    Mult Scler. 2024 Apr 14:13524585241245313. doi: 10.1177/13524585241245313.
    >> Share

  366. OZTURK B, Taskiran E, Demir S, Tuncer MA, et al
    Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study.
    Mult Scler. 2024 Apr 14:13524585241245318. doi: 10.1177/13524585241245318.
    >> Share

  367. SCHNEIDER M, Kramer J, Banks A, Moses H, et al
    New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
    Mult Scler. 2024 Apr 11:13524585241242027. doi: 10.1177/13524585241242027.
    >> Share

  368. MOCCIA M, Terracciano D, Brescia Morra V, Castaldo G, et al
    Neurofilament in clinical practice: Is the multiple sclerosis community ready?
    Mult Scler. 2024 Apr 11:13524585241246536. doi: 10.1177/13524585241246536.
    >> Share

  369. KWON S, Han KD, Jung JH, Cho EB, et al
    Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
    Mult Scler. 2024 Apr 1:13524585241237093. doi: 10.1177/13524585241237093.
    >> Share

  370. ALOISI F, Salvetti M
    EBV infection drives MS pathology: Yes.
    Mult Scler. 2024;30.
    >> Share

  371. CORTESE M, Ascherio A
    EBV infection drives MS pathology: Commentary.
    Mult Scler. 2024;30.
    >> Share

  372. 'T HART BA, van Luijn MM
    EBV infection drives MS pathology: No.
    Mult Scler. 2024;30.
    >> Share

  373. TUR C, Battiston M, Yiannakas MC, Collorone S, et al
    What contributes to disability in progressive MS? A brain and cervical cord-matched quantitative MRI study.
    Mult Scler. 2024;30.
    >> Share

  374. REEVES JA, Mohebbi M, Wicks T, Salman F, et al
    Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years.
    Mult Scler. 2024;30.
    >> Share

  375. KLISTORNER S, Barnett MH, Wang C, Parratt J, et al
    Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients.
    Mult Scler. 2024;30.
    >> Share

    March 2024
  376. PAPPOLLA A, Auger C, Sao-Aviles A, Tur C, et al
    Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
    Mult Scler. 2024 Mar 29:13524585241240653. doi: 10.1177/13524585241240653.
    >> Share

  377. SIMPSON AC, Hu C, Mowry EM, Naismith RT, et al
    Structural MRI measures are associated with fatigue severity and persistence in a large, real-world cohort of people with multiple sclerosis.
    Mult Scler. 2024 Mar 25:13524585241239473. doi: 10.1177/13524585241239473.
    >> Share

  378. SORENSEN PS, Bramow S, Magyari M, Werdelin L, et al
    Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research.
    Mult Scler. 2024 Mar 24:13524585241239506. doi: 10.1177/13524585241239506.
    >> Share

  379. MAILLART E, Redolfi S, Louapre C, Houot M, et al
    Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort.
    Mult Scler. 2024 Mar 22:13524585241238840. doi: 10.1177/13524585241238840.
    >> Share

  380. CAMPAGNA MP, Havrdova EK, Horakova D, Izquierdo G, et al
    No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.
    Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406.
    >> Share

  381. HJALGRIM H, Rostgaard K
    Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
    Mult Scler. 2024 Mar 21:13524585241237708. doi: 10.1177/13524585241237708.
    >> Share

  382. GOLDACRE R
    Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003-2023.
    Mult Scler. 2024 Mar 21:13524585241237707. doi: 10.1177/13524585241237707.
    >> Share

  383. JOHNSSON M, Stenberg YT, Farman HH, Blennow K, et al
    Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
    Mult Scler. 2024 Mar 13:13524585241237388. doi: 10.1177/13524585241237388.
    >> Share

  384. NAKAMURA K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al
    Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
    Mult Scler. 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055.
    >> Share

  385. EHLING R, Seebacher B, Brenneis C
    Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Mar 11:13524585241234789. doi: 10.1177/13524585241234789.
    >> Share

  386. HILLERT J, Bove R, Haddad LB, Hellwig K, et al
    Expert opinion on the use of contraception in people with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
    >> Share

  387. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
    Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
    >> Share

  388. KUBICKI K, Stefoski D
    Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
    Mult Scler. 2024 Mar 8:13524585241235539. doi: 10.1177/13524585241235539.
    >> Share

  389. MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
    Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
    >> Share

  390. GIULIANI G, Zilli C, Caramia F, Di Piero V, et al
    SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.
    Mult Scler. 2024 Mar 1:13524585241235535. doi: 10.1177/13524585241235535.
    >> Share

    February 2024
  391. AFZAL RM, Romme Christensen J, Gynthersen RMM, Lebech AM, et al
    Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report.
    Mult Scler. 2024 Feb 29:13524585241235542. doi: 10.1177/13524585241235542.
    >> Share

  392. KARI S, Bucciarelli F, Angles T, Oster AC, et al
    Increased levels of circulating soluble CD226 in multiple sclerosis.
    Mult Scler. 2024 Feb 29:13524585241234489. doi: 10.1177/13524585241234489.
    >> Share

  393. HEESEN C, Luhmann D
    Reply: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Feb 29:13524585241234777. doi: 10.1177/13524585241234777.
    >> Share

  394. LIM TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, et al
    Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
    Mult Scler. 2024 Feb 28:13524585241228426. doi: 10.1177/13524585241228426.
    >> Share

  395. NAKKEN O, Aarseth JH, Wergeland S, Stigum H, et al
    BCG vaccination and multiple sclerosis risk: A Norwegian cohort study.
    Mult Scler. 2024 Feb 27:13524585241230440. doi: 10.1177/13524585241230440.
    >> Share

  396. MILLER AE
    Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time for a change?
    Mult Scler. 2024 Feb 27:13524585241233999. doi: 10.1177/13524585241233999.
    >> Share

  397. KRIEGER SC, Sinks S, Huang F, Steverson J, et al
    The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis.
    Mult Scler. 2024 Feb 26:13524585241232274. doi: 10.1177/13524585241232274.
    >> Share

  398. BOAVENTURA M, Sastre-Garriga J, Rimkus CM, Rovira A, et al
    T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241233448. doi: 10.1177/13524585241233448.
    >> Share

  399. EMMA C, Vesela P, Kay P, Huseyin H, et al
    Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
    Mult Scler. 2024 Feb 22:13524585241232277. doi: 10.1177/13524585241232277.
    >> Share

  400. ERCAN MB, Kocer B, Altiparmak T, Arslan I, et al
    Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241231655. doi: 10.1177/13524585241231655.
    >> Share

  401. JALALEDDINI K, Bermel RA, Talente B, Weinstein D, et al
    A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241227372. doi: 10.1177/13524585241227372.
    >> Share

  402. ROCCA MA, D'Amore G, Valsasina P, Tedone N, et al
    2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241231155. doi: 10.1177/13524585241231155.
    >> Share

  403. ROVARIS M, Toselli E, Mendozzi L, Di Tella S, et al
    Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study.
    Mult Scler. 2024 Feb 19:13524585241230236. doi: 10.1177/13524585241230236.
    >> Share

  404. HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
    A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial.
    Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
    >> Share

  405. COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
    Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
    >> Share

  406. PATEL S, Rafferty S, Aquino L, Chadha S, et al
    VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
    Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
    >> Share

  407. KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
    Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
    >> Share

  408. MOTL RW, Russell DI, Pilutti LA, Metse AP, et al
    Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report.
    Mult Scler. 2024 Feb 9:13524585241229332. doi: 10.1177/13524585241229332.
    >> Share

  409. BELLUCCI G, Buscarinu MC, Renie R, Rinaldi V, et al
    Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach.
    Mult Scler. 2024 Feb 9:13524585241227119. doi: 10.1177/13524585241227119.
    >> Share

  410. ZIAEI A, Solomon O, Casper TC, Waltz M, et al
    Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis.
    Mult Scler. 2024 Feb 9:13524585231224685. doi: 10.1177/13524585231224685.
    >> Share

  411. GILMARTIN CG, Hoyle N, Garjani A, Dixon T, et al
    Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
    Mult Scler. 2024 Feb 7:13524585231225711. doi: 10.1177/13524585231225711.
    >> Share

  412. MCGINLEY MP, Manouchehrinia A
    The landscape of multiple sclerosis registries: Strengths and limitations.
    Mult Scler. 2024 Feb 6:13524585241228746. doi: 10.1177/13524585241228746.
    >> Share

  413. VUKUSIC S, Bourre B, Casey R, Deiva K, et al
    The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics.
    Mult Scler. 2024;30:216-226.
    >> Share

  414. GHAJARZADEH M, Fitzgerald KC, Mowry EM, Nourbakhsh B, et al
    Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS.
    Mult Scler. 2024;30:238-246.
    >> Share

  415. SCHNEIDER R, Brand-Arzamendi K, Reynold Lim T, Lee LE, et al
    Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome.
    Mult Scler. 2024;30:156-165.
    >> Share

  416. LANGDON D
    Neuropsychological assessment in MS is outdated and in need for innovation: NO.
    Mult Scler. 2024;30:152-153.
    >> Share

    January 2024
  417. NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
    Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
    Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
    >> Share

  418. SWITAL M, Drouin J, Miranda S, Bakchine S, et al
    Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
    Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
    >> Share

  419. MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
    White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study.
    Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
    >> Share

  420. HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al
    Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
    Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938.
    >> Share

  421. CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al
    Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
    Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138.
    >> Share

  422. JEANTIN L, Januel E, Labauge P, Maillart E, et al
    COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
    Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149.
    >> Share

  423. TENI FS, Machado A, Fink K, Gyllensten H, et al
    Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
    Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929.
    >> Share

  424. VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al
    Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions.
    Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848.
    >> Share

  425. TOOROP AA, Noteboom S, Steenwijk MD, Gravendeel JW, et al
    Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Mult Scler. 2024 Jan 18:13524585231225855. doi: 10.1177/13524585231225855.
    >> Share

  426. DAS J, Rog DJ, Middleton R, Rodgers JW, et al
    University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register.
    Mult Scler. 2024 Jan 17:13524585231221411. doi: 10.1177/13524585231221411.
    >> Share

  427. PORTACCIO E, Iaffaldano P
    Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggers.
    Mult Scler. 2024 Jan 11:13524585231224667. doi: 10.1177/13524585231224667.
    >> Share

  428. FRAMKE E, Thygesen LC, Malmborg M, Schou M, et al
    Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.
    Mult Scler. 2024 Jan 11:13524585231221415. doi: 10.1177/13524585231221415.
    >> Share

  429. MOTYL J
    Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs.
    Mult Scler. 2024 Jan 9:13524585231221409. doi: 10.1177/13524585231221409.
    >> Share

  430. MORROW SA
    Response to letter to the editor "Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs".
    Mult Scler. 2024 Jan 9:13524585231221412. doi: 10.1177/13524585231221412.
    >> Share

  431. VENET M, Lepine A, Maarouf A, Biotti D, et al
    Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
    Mult Scler. 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069.
    >> Share

  432. VAN LAETHEM D, Denissen S, Costers L, Descamps A, et al
    The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment.
    Mult Scler. 2024;30:121-130.
    >> Share

  433. HUGOS CL, Joos SK, Perumean-Chaney SE, Cutter GR, et al
    Stretching is not essential for managing MS spasticity: A randomized controlled trial.
    Mult Scler. 2024;30:89-102.
    >> Share

  434. DE GIER M, Beckerman H, Twisk JW, Knoop H, et al
    Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial.
    Mult Scler. 2024;30:71-79.
    >> Share

  435. WRIGHT SL, Thompson AJ
    Managing patients with late-onset neutropenia during treatment with ocrelizumab.
    Mult Scler. 2024;30:134.
    >> Share

  436. KOCH-HENRIKSEN NI, Thygesen LC, Sorensen PS, Magyari M, et al
    Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS.
    Mult Scler. 2024;30:113-120.
    >> Share

    December 2023
  437. PARCIAK T, Geys L, Helme A, van der Mei I, et al
    Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.
    Mult Scler. 2023 Dec 23:13524585231216004. doi: 10.1177/13524585231216004.
    >> Share

  438. DOBSON R, Holden D, Vickaryous N, Bestwick J, et al
    A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
    Mult Scler. 2023 Dec 22:13524585231215268. doi: 10.1177/13524585231215268.
    >> Share

  439. NAISMITH RT, Cohen JA, Bar-Or A, Comi G, et al
    Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
    Mult Scler. 2023 Dec 21:13524585231216854. doi: 10.1177/13524585231216854.
    >> Share

  440. TAZZA F, Schiavi S, Leveraro E, Cellerino M, et al
    Clinical and radiological correlates of apathy in multiple sclerosis.
    Mult Scler. 2023 Dec 14:13524585231217918. doi: 10.1177/13524585231217918.
    >> Share

  441. DABOUL L, O'Donnell CM, Amin M, Rodrigues P, et al
    A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
    Mult Scler. 2023 Dec 13:13524585231214360. doi: 10.1177/13524585231214360.
    >> Share

  442. DALLA COSTA G, Nos C, Zabalza A, Buron M, et al
    A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
    Mult Scler. 2023 Dec 12:13524585231214362. doi: 10.1177/13524585231214362.
    >> Share

  443. BRUCE JM, Cozart JS, Shook RP, Befort C, et al
    Modifying diet and exercise in multiple sclerosis (MoDEMS): A randomized controlled trial for behavioral weight loss in adults with multiple sclerosis and obesity.
    Mult Scler. 2023;29:1860-1871.
    >> Share

  444. SACCO S, Virupakshaiah A, Papinutto N, Schoeps VA, et al
    Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease.
    Mult Scler. 2023;29:1736-1747.
    >> Share

  445. LUBLIN FD
    Worsening MS-A reappraisal of how we characterize the MS disease course.
    Mult Scler. 2023;29:1699-1700.
    >> Share

  446. SAMADZADEH S, Olesen MN, Wirenfeldt M, Moller S, et al
    Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
    Mult Scler. 2023;29:1721-1735.
    >> Share

  447. PROSCHMANN U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, et al
    Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
    Mult Scler. 2023;29:1849-1859.
    >> Share

  448. MORROW SA, Weinstock ZL, Mirmosayyeb O, Conway D, et al
    Detecting isolated cognitive relapses in persons with MS.
    Mult Scler. 2023;29:1786-1794.
    >> Share

    November 2023
  449. MATTIESING RM, Kramer E, Strijbis EM, Brouwer I, et al
    Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
    Mult Scler. 2023 Nov 29:13524585231212879. doi: 10.1177/13524585231212879.
    >> Share

  450. ZHAO T, Taylor BV, Campbell JA, Palmer AJ, et al
    The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
    Mult Scler. 2023 Nov 24:13524585231213230. doi: 10.1177/13524585231213230.
    >> Share

  451. MONTEIRO IR, Moccia M
    Mobile health interventions in multiple sclerosis: Bringing empowerment into clinical practice.
    Mult Scler. 2023 Nov 20:13524585231214879. doi: 10.1177/13524585231214879.
    >> Share

  452. CASTANO-AMORES C, Nieto-Gomez P
    The crossroads of multiple sclerosis and cancer: Urgent call for clinical direction.
    Mult Scler. 2023 Nov 20:13524585231214171. doi: 10.1177/13524585231214171.
    >> Share

  453. LADAKIS DC, Reyes-Mantilla MI, Gadani SP, Mace JW, et al
    Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Mult Scler. 2023 Nov 20:13524585231213164. doi: 10.1177/13524585231213164.
    >> Share

  454. NIELSEN NM, Frisch M, Gortz S, Stenager E, et al
    Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study.
    Mult Scler. 2023 Nov 19:13524585231208310. doi: 10.1177/13524585231208310.
    >> Share

  455. BROCHET B, Solari A, Lechner-Scott J, Piehl F, et al
    Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Mult Scler. 2023 Nov 18:13524585231205962. doi: 10.1177/13524585231205962.
    >> Share

  456. NICHOLSON S, Russo AW, Brewer K, Bien H, et al
    The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
    Mult Scler. 2023 Nov 10:13524585231204710. doi: 10.1177/13524585231204710.
    >> Share

  457. BOU RJEILY N, Fitzgerald KC, Mowry EM
    Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
    Mult Scler. 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311.
    >> Share

  458. AMEZCUA L, Robers MV, Soneji D, Manouvakhova O, et al
    Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
    Mult Scler. 2023 Nov 9:13524585231209016. doi: 10.1177/13524585231209016.
    >> Share

  459. ZICCARDI S, Fuchs T, Dwyer MG, Zivadinov R, et al
    Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis.
    Mult Scler. 2023 Nov 9:13524585231208331. doi: 10.1177/13524585231208331.
    >> Share

  460. VAN KEMPEN ZL, van Dam KP, Keijser JB, Stalman EW, et al
    Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
    Mult Scler. 2023 Nov 9:13524585231207761. doi: 10.1177/13524585231207761.
    >> Share

  461. FEINSTEIN A
    The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.
    Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178.
    >> Share

  462. CHASE E, Chen V, Martin K, Lane M, et al
    A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial.
    Mult Scler. 2023;29:1659-1675.
    >> Share

  463. WEINSTOCK ZL, Jaworski M 3rd, Dwyer MG, Jakimovski D, et al
    Auditory Test of Processing Speed: Preliminary validation of a smartphone-based test of mental speed.
    Mult Scler. 2023;29:1646-1658.
    >> Share

  464. WISHART M, Everest MR, Morrow SA, Rose J, et al
    Establishing the consistency of a voice recognition symbol digit modalities test analogue.
    Mult Scler. 2023;29:1676-1679.
    >> Share

  465. BOCCIA VD, Saitta L, Inglese M, Lapucci C, et al
    Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient.
    Mult Scler. 2023;29:1688-1692.
    >> Share

    October 2023
  466. ONTANEDA D, Amezcua L
    Re-thinking race and geography in multiple sclerosis.
    Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969.
    >> Share

  467. SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al
    Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708.
    >> Share

  468. HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al
    Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089.
    >> Share

  469. PORWAL MH, Obeidat AZ
    A closer look at reported colitis in association with multiple sclerosis treatments.
    Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964.
    >> Share

  470. LEARMONTH YC, P Herring M, Russell DI, Pilutti LA, et al
    Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.
    Mult Scler. 2023 Oct 26:13524585231204459. doi: 10.1177/13524585231204459.
    >> Share

  471. RAMARI C, Awadia Z, Bansi J, Casey B, et al
    The MoxFo initiative - outcomes: Outcome measures in studies of exercise training in multiple sclerosis; scoping review of reviews and classification according to the ICF framework.
    Mult Scler. 2023 Oct 26:13524585231204451. doi: 10.1177/13524585231204451.
    >> Share

  472. DALGAS U, Riemenschneider M, Gold SM, Kalron A, et al
    The MoXFo initiative - study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis.
    Mult Scler. 2023 Oct 26:13524585231204456. doi: 10.1177/13524585231204456.
    >> Share

  473. MANSOUBI M, Learmonth YC, Mayo N, Collet J, et al
    The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research.
    Mult Scler. 2023 Oct 26:13524585231204460. doi: 10.1177/13524585231204460.
    >> Share

  474. ROSENKRANZ SC, Ploughman M, Hvid LG, Zimmer P, et al
    The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies.
    Mult Scler. 2023 Oct 26:13524585231204453. doi: 10.1177/13524585231204453.
    >> Share

  475. MOTL RW, Casey B, Learmonth YC, Latimer-Cheung A, et al
    The MoXFo initiative - adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research.
    Mult Scler. 2023 Oct 26:13524585231204446. doi: 10.1177/13524585231204446.
    >> Share

  476. ZHANG Y, Atkinson J, Burd CE, Graves J, et al
    Biological aging in multiple sclerosis.
    Mult Scler. 2023 Oct 25:13524585231204122. doi: 10.1177/13524585231204122.
    >> Share

  477. BEREK K, Hegen H, Auer M, Barket R, et al
    Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
    Mult Scler. 2023 Oct 18:13524585231201093. doi: 10.1177/13524585231201093.
    >> Share

  478. KOCH MW, Moral E, Brieva L, Mostert J, et al
    Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
    Mult Scler. 2023 Oct 13:13524585231202320. doi: 10.1177/13524585231202320.
    >> Share

  479. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
    Vaccination frequency in people newly diagnosed with multiple sclerosis.
    Mult Scler. 2023 Oct 13:13524585231199084. doi: 10.1177/13524585231199084.
    >> Share

  480. REYES S, Otero-Romero S
    Rethinking vaccination in multiple sclerosis: The way forward.
    Mult Scler. 2023 Oct 3:13524585231204126. doi: 10.1177/13524585231204126.
    >> Share

  481. LAPUCCI C, Boccia VD, Sirito T, Cellerino M, et al
    Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
    Mult Scler. 2023 Oct 3:13524585231204121. doi: 10.1177/13524585231204121.
    >> Share

  482. TIEPPO EMS, Silva GD, Silva TFFD, Araujo RS, et al
    Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process-Cohort study.
    Mult Scler. 2023 Oct 3:13524585231199323. doi: 10.1177/13524585231199323.
    >> Share

  483. JACOBER SLS, Disanto G, Sacco R, Meng D, et al
    Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
    Mult Scler. 2023 Oct 3:13524585231199820. doi: 10.1177/13524585231199820.
    >> Share

  484. UHER T, Adzima A, Srpova B, Noskova L, et al
    Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.
    Mult Scler. 2023;29.
    >> Share

  485. WU Y, Geraldes R, Jurynczyk M, Palace J, et al
    Double-negative neuromyelitis optica spectrum disorder.
    Mult Scler. 2023;29.
    >> Share

  486. THOMPSON AJ, Moccia M, Amato MP, Calabresi PA, et al
    Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.
    Mult Scler. 2023;29.
    >> Share

    September 2023
  487. ANDERSON JR, Fitzgerald KC, Murrough JW, Katz Sand IB, et al
    Depression symptoms and cognition in multiple sclerosis: Longitudinal evidence of a specific link to executive control.
    Mult Scler. 2023 Sep 29:13524585231198746. doi: 10.1177/13524585231198746.
    >> Share

  488. CERDA-FUERTES N, Stoessel M, Mickeliunas G, Pless S, et al
    Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
    Mult Scler. 2023 Sep 29:13524585231198760. doi: 10.1177/13524585231198760.
    >> Share

  489. VERCELLINO M, Costantini G, Cogoni M, Lequio L, et al
    Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
    Mult Scler. 2023 Sep 23:13524585231199031. doi: 10.1177/13524585231199031.
    >> Share

  490. FREEDMAN DE, Krysko KM, Feinstein A
    Intimate partner violence and multiple sclerosis.
    Mult Scler. 2023 Sep 21:13524585231197926. doi: 10.1177/13524585231197926.
    >> Share

  491. CARVAJAL R, Tur C, Martinez-Gomez X, Bollo L, et al
    A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
    Mult Scler. 2023 Sep 20:13524585231200303. doi: 10.1177/13524585231200303.
    >> Share

  492. MORALES-RODRIGUEZ D, Anderson A, Nylander A, Hsu S, et al
    Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis.
    Mult Scler. 2023 Sep 16:13524585231197056. doi: 10.1177/13524585231197056.
    >> Share

  493. KRAJNC N, Schmidbauer V, Leinkauf J, Haider L, et al
    Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis.
    Mult Scler. 2023 Sep 15:13524585231197954. doi: 10.1177/13524585231197954.
    >> Share

  494. BOSE G, Healy BC, Barro C, Moreira Ferreira VF, et al
    Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis.
    Mult Scler. 2023 Sep 15:13524585231198751. doi: 10.1177/13524585231198751.
    >> Share

  495. MARTIN SJ, Brand-Arzamendi K, Saab G, Muccilli A, et al
    GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis.
    Mult Scler. 2023 Sep 12:13524585231195861. doi: 10.1177/13524585231195861.
    >> Share

  496. MOGHAVEM N, Castaneda GDR, Chatfield AJ, Amezcua L, et al
    The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review.
    Mult Scler. 2023 Sep 12:13524585231197275. doi: 10.1177/13524585231197275.
    >> Share

  497. WANG Y, Bou Rjeily N, Koshorek J, Grkovski R, et al
    Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States.
    Mult Scler. 2023 Sep 12:13524585231196795. doi: 10.1177/13524585231196795.
    >> Share

  498. BRUNO A, Buttari F, Dolcetti E, Azzolini F, et al
    Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
    Mult Scler. 2023 Sep 12:13524585231197928. doi: 10.1177/13524585231197928.
    >> Share

  499. HAUSER SL, Zielman R, Das Gupta A, Xi J, et al
    Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Mult Scler. 2023 Sep 11:13524585231195346. doi: 10.1177/13524585231195346.
    >> Share

  500. DEJONGE SR, DuBose NG, Pilutti LA, Motl RW, et al
    Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic fitness account for group differences?
    Mult Scler. 2023 Sep 11:13524585231199030. doi: 10.1177/13524585231199030.
    >> Share

    August 2023
  501. HARDY TA
    Pseudocystic demyelination in multiple sclerosis.
    Mult Scler. 2023 Aug 25:13524585231193365. doi: 10.1177/13524585231193365.
    >> Share

  502. CLUSE F, Fenouil T, Vukusic S, Ducray F, et al
    Pseudocystic inflammatory demyelinating lesions in multiple sclerosis: A clinical, radiological, and pathological description.
    Mult Scler. 2023 Aug 25:13524585231193345. doi: 10.1177/13524585231193345.
    >> Share

  503. BAR-OR A, Cross AH, Cunningham AL, Hyvert Y, et al
    Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
    Mult Scler. 2023 Aug 25:13524585231192460. doi: 10.1177/13524585231192460.
    >> Share

  504. RAIMO S, Santangelo G, Cropano M, Gaita M, et al
    Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis.
    Mult Scler. 2023 Aug 21:13524585231192469. doi: 10.1177/13524585231192469.
    >> Share

  505. BALSHI A, Saart E, Pandeya S, Dempsey J, et al
    High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate.
    Mult Scler. 2023 Aug 12:13524585231189641. doi: 10.1177/13524585231189641.
    >> Share

  506. FAN JH, Alexander J, Poole S, Wijangco J, et al
    Characteristics of multiple sclerosis and demyelinating disease in an Asian American population.
    Mult Scler. 2023 Aug 7:13524585231188486. doi: 10.1177/13524585231188486.
    >> Share

  507. MARRIE RA, Bernstein CN, Dolovich C, Bolton JM, et al
    Within-person fluctuations over three years in depression, anxiety, fatigue, and health-related quality of life in multiple sclerosis.
    Mult Scler. 2023 Aug 3:13524585231190771. doi: 10.1177/13524585231190771.
    >> Share

  508. NAKAMURA K, Zheng Y, Mahajan KR, Cohen JA, et al
    Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
    Mult Scler. 2023 Aug 3:13524585231187289. doi: 10.1177/13524585231187289.
    >> Share

  509. WESSELS MH, Van Lierop ZY, Noteboom S, Strijbis EM, et al
    Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Mult Scler. 2023 Aug 2:13524585231188625. doi: 10.1177/13524585231188625.
    >> Share

  510. TAYLOR LA, Mhizha-Murira JR, Law G, Evangelou N, et al
    Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis.
    Mult Scler. 2023 Aug 1:13524585231189470. doi: 10.1177/13524585231189470.
    >> Share

  511. COTE SE, Wagshul ME, Foley FW, Lipton ML, et al
    Caudate volume and symptoms of apathy in older adults with multiple sclerosis.
    Mult Scler. 2023 Aug 1:13524585231188096. doi: 10.1177/13524585231188096.
    >> Share

  512. GRAY E, Amjad A, Robertson J, Beveridge J, et al
    Enhancing involvement of people with multiple sclerosis in clinical trial design.
    Mult Scler. 2023;29:1162-1173.
    >> Share

  513. SORMANI MP, Chataway J, Kent DM, Marrie RA, et al
    Assessing heterogeneity of treatment effect in multiple sclerosis trials.
    Mult Scler. 2023;29:1158-1161.
    >> Share

  514. MARRIE RA, Sormani MP, Apap Mangion S, Bovis F, et al
    Improving the efficiency of clinical trials in multiple sclerosis.
    Mult Scler. 2023;29:1136-1148.
    >> Share

  515. FINLAYSON M, Al-Mashita L, Sandhu R
    Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: A scoping review.
    Mult Scler. 2023;29:1149-1157.
    >> Share

  516. MARRIE RA, Chataway J, Bierer BE, Finlayson M, et al
    Enhancing diversity of clinical trial populations in multiple sclerosis.
    Mult Scler. 2023;29:1174-1185.
    >> Share

  517. FINLAYSON M, Feys P, Dalgas U, Kos D, et al
    Intermediate outcomes for clinical trials of multiple sclerosis rehabilitation interventions: Conceptual and practical considerations.
    Mult Scler. 2023;29:1186-1194.
    >> Share

  518. GIOVANNONI G
    Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.
    Mult Scler. 2023;29:1068-1069.
    >> Share

  519. STRIJBIS E, Koch MW, de Jong BA
    Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.
    Mult Scler. 2023;29:1066-1067.
    >> Share

  520. GOVEROVER Y, Chiaravalloti N
    Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
    Mult Scler. 2023;29:1064-1065.
    >> Share

  521. COHEN M, Thomel-Rocchi O, Siva A, Okuda DT, et al
    Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
    Mult Scler. 2023;29:1099-1106.
    >> Share

    July 2023
  522. CAVALLA P, Vercellino M
    May Mediterranean diet contribute to reduce risk of multiple sclerosis?
    Mult Scler. 2023 Jul 29:13524585231190342. doi: 10.1177/13524585231190342.
    >> Share

  523. GUNZLER DD, De Nadai AS, Miller DM, Ontaneda D, et al
    Long-term trajectories of ambulatory impairment in multiple sclerosis.
    Mult Scler. 2023 Jul 28:13524585231187521. doi: 10.1177/13524585231187521.
    >> Share

  524. JAWORSKI MG 3RD, Gillies JK, Youngs M, Wojcik C, et al
    Predicting employment deterioration with the Processing Speed Test (PST) and SDMT in multiple sclerosis.
    Mult Scler. 2023 Jul 28:13524585231187283. doi: 10.1177/13524585231187283.
    >> Share

  525. GOVEROVER Y, Amber S, John D
    Assessing everyday functional activity in cognitively impaired people with multiple sclerosis: The use of Actual Reality(TM).
    Mult Scler. 2023 Jul 26:13524585231185048. doi: 10.1177/13524585231185048.
    >> Share

  526. DE GIER M, Beckerman H, Twisk J, Knoop H, et al
    Blended versus face-to-face cognitive behavioural therapy for severe fatigue in patients with multiple sclerosis: A non-inferiority RCT.
    Mult Scler. 2023 Jul 25:13524585231185462. doi: 10.1177/13524585231185462.
    >> Share

  527. TITBALL RW, Lewis N, Nicholas R
    Is Clostridium perfringens epsilon toxin associated with multiple sclerosis?
    Mult Scler. 2023 Jul 22:13524585231186899. doi: 10.1177/13524585231186899.
    >> Share

  528. COHEN JA
    Commentary: Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol (in press).
    Mult Scler. 2023 Jul 20:13524585231188097. doi: 10.1177/13524585231188097.
    >> Share

  529. BOLES GS, Hillert J, Ramanujam R, Westerlind H, et al
    The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study.
    Mult Scler. 2023 Jul 12:13524585231185258. doi: 10.1177/13524585231185258.
    >> Share

  530. ORLANDO CM, Perez CA, Agyei P, Elsehety M, et al
    Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis.
    Mult Scler. 2023 Jul 12:13524585231185046. doi: 10.1177/13524585231185046.
    >> Share

  531. SIPILA JO, Viitala M, Hanninen A, Soilu-Hanninen M, et al
    Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis.
    Mult Scler. 2023 Jul 10:13524585231185045. doi: 10.1177/13524585231185045.
    >> Share

  532. NEYAL N, Keegan BM, Kantarci OH, Zeydan B, et al
    Coexistence of multiple sclerosis and spinocerebellar ataxia type-8.
    Mult Scler. 2023 Jul 3:13524585231180549. doi: 10.1177/13524585231180549.
    >> Share

  533. KLINEOVA S, Farber RS, DeAngelis T, Leung T, et al
    Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
    Mult Scler. 2023;29:990-1000.
    >> Share

  534. ZALOUM SA, Wood CH, Tank P, Upcott M, et al
    Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
    Mult Scler. 2023;29:979-989.
    >> Share

  535. REEVES JA, Weinstock Z, Zivadinov R, Dwyer MG, et al
    Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse.
    Mult Scler. 2023;29:1033-1038.
    >> Share

  536. HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
    A taxonomic approach to cognitive diagnostics is viable and achievable in MS.
    Mult Scler. 2023;29:1040-1042.
    >> Share

    June 2023
  537. HE AH, Manouchehrinia A, Glaser A, Ciccarelli O, et al
    Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis.
    Mult Scler. 2023 Jun 30:13524585231181578. doi: 10.1177/13524585231181578.
    >> Share

  538. ALFREDSSON L, Olsson T, Hedstrom AK
    Inverse association between Mediterranean diet and risk of multiple sclerosis.
    Mult Scler. 2023 Jun 27:13524585231181841. doi: 10.1177/13524585231181841.
    >> Share

  539. JIANG X, Shen C, Teunissen CE, Wessels M, et al
    Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
    Mult Scler. 2023 Jun 15:13524585231176732. doi: 10.1177/13524585231176732.
    >> Share

  540. SMOOT K, Marginean H, Gervasi-Follmar T, Chen C, et al
    Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Mult Scler. 2023 Jun 15:13524585231175284. doi: 10.1177/13524585231175284.
    >> Share

  541. OTERO-ROMERO S, Lebrun-Frenay C, Reyes S, Amato MP, et al
    ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
    Mult Scler. 2023 Jun 9:13524585231168043. doi: 10.1177/13524585231168043.
    >> Share

  542. NYLANDER AN, Singh J, Poole S, Anderson A, et al
    Clinical course of multiple sclerosis and patient experiences during breast cancer treatment.
    Mult Scler. 2023 Jun 8:13524585231175975. doi: 10.1177/13524585231175975.
    >> Share

  543. DELAVAL S, Dequirez PL, Hentzen C, Baron M, et al
    Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee o
    Mult Scler. 2023 Jun 2:13524585231174580. doi: 10.1177/13524585231174580.
    >> Share

  544. LUBLIN FD, Krieger SC
    MS becomes a treatable disease: 30 years later.
    Mult Scler. 2023;29:789-792.
    >> Share

  545. REDENBAUGH V, Chia NH, Cacciaguerra L, McCombe JA, et al
    Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
    Mult Scler. 2023;29:799-808.
    >> Share

  546. LEBRUN-FRENAY C, Okuda DT
    Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes.
    Mult Scler. 2023;29:793-795.
    >> Share

  547. INGLESE M, Amato MP
    Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary.
    Mult Scler. 2023;29:797-798.
    >> Share

  548. SMETS I
    Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated - NO.
    Mult Scler. 2023;29:795-797.
    >> Share

  549. HUMMERT MW, Stern C, Paul F, Duchow A, et al
    Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
    Mult Scler. 2023;29:819-831.
    >> Share

    May 2023
  550. BANWELL B
    Pediatric multiple sclerosis: The 2022 ECTRIMS lecture.
    Mult Scler. 2023 May 30:13524585231171047. doi: 10.1177/13524585231171047.
    >> Share

  551. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
    Sars-CoV2 infection in pregnant women with multiple sclerosis.
    Mult Scler. 2023 May 26:13524585231176174. doi: 10.1177/13524585231176174.
    >> Share

  552. ALSHEHRI E, Cohen JA, Ontaneda D, Nakamura K, et al
    The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
    Mult Scler. 2023 May 19:13524585231172490. doi: 10.1177/13524585231172490.
    >> Share

  553. VIRUPAKSHAIAH A, Ladakis DC, Nourbakhsh B, Bhargava P, et al
    Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.
    Mult Scler. 2023 May 18:13524585231171517. doi: 10.1177/13524585231171517.
    >> Share

  554. VALENTINE TR, Kratz AL, Kaplish N, Chervin RD, et al
    Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains.
    Mult Scler. 2023 May 17:13524585231169465. doi: 10.1177/13524585231169465.
    >> Share

  555. CAPUANO R, Prosperini L, Altieri M, Lorefice L, et al
    Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
    Mult Scler. 2023 May 11:13524585231167515. doi: 10.1177/13524585231167515.
    >> Share

  556. SAUL AM, Taylor BV, Blizzard L, Simpson-Yap S, et al
    A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study.
    Mult Scler. 2023 May 6:13524585231167739. doi: 10.1177/13524585231167739.
    >> Share

  557. KOLIND S, Gaetano L, Assemlal HE, Bernasconi C, et al
    Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
    Mult Scler. 2023;29:741-747.
    >> Share

    April 2023
  558. MARRIE RA
    The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward.
    Mult Scler. 2023 Apr 26:13524585231167740. doi: 10.1177/13524585231167740.
    >> Share

  559. FINK K, Gorczyca A, Alping P, Englund S, et al
    Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study.
    Mult Scler. 2023 Apr 18:13524585231161492. doi: 10.1177/13524585231161492.
    >> Share

  560. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Michaux K, et al
    Employment status, productivity loss, and associated factors among people with multiple sclerosis.
    Mult Scler. 2023 Apr 15:13524585231164295. doi: 10.1177/13524585231164295.
    >> Share

  561. ELLIOTT C, Rudko DA, Arnold DL, Fetco D, et al
    Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
    Mult Scler. 2023 Apr 10:13524585231162262. doi: 10.1177/13524585231162262.
    >> Share

  562. PALLADINO R, Marrie RA, Majeed A, Chataway J, et al
    Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.
    Mult Scler. 2023 Apr 7:13524585231164296. doi: 10.1177/13524585231164296.
    >> Share

  563. GIOVANNONI G, Boyko A, Correale J, Edan G, et al
    Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Mult Scler. 2023 Apr 3:13524585231161494. doi: 10.1177/13524585231161494.
    >> Share

  564. SATYANARAYAN S, Cutter G, Krieger S, Cofield S, et al
    The impact of relapse definition and measures of durability on MS clinical trial outcomes.
    Mult Scler. 2023;29.
    >> Share

  565. WITTAYER M, Weber CE, Kittel M, Platten M, et al
    Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions.
    Mult Scler. 2023;29.
    >> Share

  566. KLISTORNER S, Van der Walt A, Barnett MH, Butzkueven H, et al
    Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis.
    Mult Scler. 2023;29.
    >> Share

  567. ROTSTEIN DL, Wolfson C, Carruthers R, Freedman MS, et al
    A national case-control study investigating demographic and environmental factors associated with NMOSD.
    Mult Scler. 2023;29.
    >> Share

  568. TOHYAMA S, Oh J, Timm M, Cheng JC, et al
    Should trigeminal neuralgia be considered a clinically isolated syndrome?
    Mult Scler. 2023;29.
    >> Share

  569. ROMAN S
    A journey with no roadmap-The need for validated criteria of the MS prodrome.
    Mult Scler. 2023;29.
    >> Share

    March 2023
  570. OTTO C, Schwarz T, Jeworowski LM, Schmidt ML, et al
    Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.
    Mult Scler. 2023 Mar 28:13524585231161253. doi: 10.1177/13524585231161253.
    >> Share

  571. SIMON S, Nauta IM, Hillebrand A, Schoonheim MM, et al
    Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.
    Mult Scler. 2023 Mar 25:13524585231159817. doi: 10.1177/13524585231159817.
    >> Share

  572. GHEZZI A, Neuteboom RF
    The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized T
    Mult Scler. 2023 Mar 23:13524585231161148. doi: 10.1177/13524585231161148.
    >> Share

  573. SCHREINER T, Wilson-Murphy M, Mendelt-Tillema J, Waltz M, et al
    Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.
    Mult Scler. 2023 Mar 23:13524585231151948. doi: 10.1177/13524585231151948.
    >> Share

  574. MARRODAN M, Piedrabuena MA, Gaitan MI, Fiol MP, et al
    Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina.
    Mult Scler. 2023 Mar 21:13524585231157276. doi: 10.1177/13524585231157276.
    >> Share

  575. MOTL RW, Kidwell-Chandler A, Sandroff BM, Pilutti LA, et al
    Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project.
    Mult Scler. 2023;29:415-426.
    >> Share

  576. KUHLE J, Chitnis T, Banwell B, Tardieu M, et al
    Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Mult Scler. 2023;29:385-394.
    >> Share

  577. TOOROP AA, Steenhuis M, Loeff FC, Weijers SS, et al
    Fingerprick blood samples to measure serum natalizumab concentrations.
    Mult Scler. 2023;29:457-460.
    >> Share

    February 2023
  578. DARUWALLA C, Shaygannejad V, Ozakbas S, Havrdova EK, et al
    Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
    Mult Scler. 2023 Feb 27:13524585231151951. doi: 10.1177/13524585231151951.
    >> Share

    October 2021
  579. MHANNA E, Nouchi A, Louapre C, De Paz R, et al
    Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
    Mult Scler. 2021;27:1794-1798.
    >> Share

  580. DE MOL CL, Bruijstens AL, Jansen PR, Dremmen M, et al
    Prevalence of radiologically isolated syndrome in a pediatric population-based cohort: A longitudinal description of a rare diagnosis.
    Mult Scler. 2021;27:1790-1793.
    >> Share

  581. CAPUANO R, Zubizarreta I, Alba-Arbalat S, Sepulveda M, et al
    Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability.
    Mult Scler. 2021;27:1706-1716.
    >> Share

  582. ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
    Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
    Mult Scler. 2021;27:1643-1656.
    >> Share

    September 2021
  583. IAFFALDANO P, Lucisano G, Butzkueven H, Hillert J, et al
    Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network.
    Mult Scler. 2021;27:1543-1555.
    >> Share

  584. DALLA COSTA G, Croese T, Pisa M, Finardi A, et al
    CSF extracellular vesicles and risk of disease activity after a first demyelinating event.
    Mult Scler. 2021;27:1606-1610.
    >> Share

  585. SCHNEIDER-HOHENDORF T, Schulte-Mecklenbeck A, Ostkamp P, Janoschka C, et al
    High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
    Mult Scler. 2021;27:1491-1496.
    >> Share

  586. COHEN M, Mondot L, Bucciarelli F, Pignolet B, et al
    BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
    Mult Scler. 2021;27:1556-1563.
    >> Share

  587. THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
    Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
    Mult Scler. 2021;27:1477-1485.
    >> Share

    August 2021
  588. YAVARPOUR-BALI H, Ghasemi-Kasman M
    The role of inflammasomes in multiple sclerosis.
    Mult Scler. 2021;27:1323-1331.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016